CA2541348A1 - Methods for assessing, improving, or maintaining urogenital health in postmenopausal women - Google Patents
Methods for assessing, improving, or maintaining urogenital health in postmenopausal women Download PDFInfo
- Publication number
- CA2541348A1 CA2541348A1 CA002541348A CA2541348A CA2541348A1 CA 2541348 A1 CA2541348 A1 CA 2541348A1 CA 002541348 A CA002541348 A CA 002541348A CA 2541348 A CA2541348 A CA 2541348A CA 2541348 A1 CA2541348 A1 CA 2541348A1
- Authority
- CA
- Canada
- Prior art keywords
- vaginal
- alkyl
- vagina
- health
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000036541 health Effects 0.000 title claims abstract description 58
- 238000000034 method Methods 0.000 title claims abstract description 46
- 210000001215 vagina Anatomy 0.000 claims description 37
- 208000012287 Prolapse Diseases 0.000 claims description 32
- 206010046914 Vaginal infection Diseases 0.000 claims description 21
- 230000002485 urinary effect Effects 0.000 claims description 20
- 206010047791 Vulvovaginal dryness Diseases 0.000 claims description 19
- 206010056530 Vulvovaginal pruritus Diseases 0.000 claims description 17
- 208000019206 urinary tract infection Diseases 0.000 claims description 15
- 210000004877 mucosa Anatomy 0.000 claims description 14
- 238000011156 evaluation Methods 0.000 claims description 12
- 102000009151 Luteinizing Hormone Human genes 0.000 claims description 10
- 108010073521 Luteinizing Hormone Proteins 0.000 claims description 10
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 10
- 206010046814 Uterine prolapse Diseases 0.000 claims description 10
- 229940040129 luteinizing hormone Drugs 0.000 claims description 10
- 206010046940 Vaginal prolapse Diseases 0.000 claims description 8
- 229940088597 hormone Drugs 0.000 claims description 8
- 239000005556 hormone Substances 0.000 claims description 8
- 229960005309 estradiol Drugs 0.000 claims description 7
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 6
- 229930182833 estradiol Natural products 0.000 claims description 6
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 5
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 5
- 229940028334 follicle stimulating hormone Drugs 0.000 claims description 5
- 229960003604 testosterone Drugs 0.000 claims description 5
- AEMFNILZOJDQLW-QAGGRKNESA-N androst-4-ene-3,17-dione Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1 AEMFNILZOJDQLW-QAGGRKNESA-N 0.000 claims description 4
- 229960005471 androstenedione Drugs 0.000 claims description 4
- AEMFNILZOJDQLW-UHFFFAOYSA-N androstenedione Natural products O=C1CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CCC2=C1 AEMFNILZOJDQLW-UHFFFAOYSA-N 0.000 claims description 4
- 230000011748 cell maturation Effects 0.000 claims description 4
- 238000004904 shortening Methods 0.000 claims description 4
- 210000003905 vulva Anatomy 0.000 claims description 4
- 230000036470 plasma concentration Effects 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 abstract description 135
- 229940011871 estrogen Drugs 0.000 abstract description 86
- 239000000262 estrogen Substances 0.000 abstract description 86
- 239000000556 agonist Substances 0.000 abstract description 63
- 239000005557 antagonist Substances 0.000 abstract description 62
- 125000000623 heterocyclic group Chemical group 0.000 abstract description 34
- 125000005842 heteroatom Chemical group 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 13
- 238000011282 treatment Methods 0.000 abstract description 12
- 125000002837 carbocyclic group Chemical group 0.000 abstract description 7
- 230000002411 adverse Effects 0.000 abstract description 4
- 125000003277 amino group Chemical group 0.000 abstract description 3
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 91
- 125000001424 substituent group Chemical group 0.000 description 48
- 150000003839 salts Chemical class 0.000 description 47
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 45
- 229910052739 hydrogen Inorganic materials 0.000 description 41
- -1 bicyclic amine Chemical class 0.000 description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 36
- 229910052799 carbon Inorganic materials 0.000 description 32
- 239000001257 hydrogen Substances 0.000 description 31
- 125000003545 alkoxy group Chemical group 0.000 description 29
- 239000000651 prodrug Substances 0.000 description 28
- 229940002612 prodrug Drugs 0.000 description 28
- 125000004093 cyano group Chemical group *C#N 0.000 description 27
- 150000002148 esters Chemical class 0.000 description 27
- 239000003826 tablet Substances 0.000 description 24
- 229910052736 halogen Inorganic materials 0.000 description 23
- 150000002367 halogens Chemical class 0.000 description 23
- 150000002431 hydrogen Chemical group 0.000 description 21
- 150000001204 N-oxides Chemical class 0.000 description 19
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 19
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 19
- 125000004414 alkyl thio group Chemical group 0.000 description 19
- 230000003287 optical effect Effects 0.000 description 19
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 19
- 239000002775 capsule Substances 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 206010021639 Incontinence Diseases 0.000 description 17
- 125000004432 carbon atom Chemical group C* 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 125000005843 halogen group Chemical group 0.000 description 17
- 210000001144 hymen Anatomy 0.000 description 17
- 125000004423 acyloxy group Chemical group 0.000 description 16
- 125000003282 alkyl amino group Chemical group 0.000 description 16
- 125000004951 trihalomethoxy group Chemical group 0.000 description 16
- 125000004953 trihalomethyl group Chemical group 0.000 description 16
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 15
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 206010006187 Breast cancer Diseases 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 13
- 229910052792 caesium Inorganic materials 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 12
- 201000004989 Enterocele Diseases 0.000 description 11
- 206010019909 Hernia Diseases 0.000 description 11
- 201000008100 Vaginitis Diseases 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 210000003903 pelvic floor Anatomy 0.000 description 11
- 206010038084 Rectocele Diseases 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 210000000664 rectum Anatomy 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- 206010003694 Atrophy Diseases 0.000 description 9
- 208000035143 Bacterial infection Diseases 0.000 description 9
- 206010011803 Cystocele Diseases 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 230000037444 atrophy Effects 0.000 description 9
- 208000022362 bacterial infectious disease Diseases 0.000 description 9
- 125000000753 cycloalkyl group Chemical group 0.000 description 9
- 230000007794 irritation Effects 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 206010027566 Micturition urgency Diseases 0.000 description 8
- 206010036018 Pollakiuria Diseases 0.000 description 8
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000003756 cervix mucus Anatomy 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 230000035800 maturation Effects 0.000 description 8
- 230000009245 menopause Effects 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 229920006395 saturated elastomer Polymers 0.000 description 8
- 208000022934 urinary frequency Diseases 0.000 description 8
- 230000036318 urination frequency Effects 0.000 description 8
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 7
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 7
- 206010046543 Urinary incontinence Diseases 0.000 description 7
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 210000002919 epithelial cell Anatomy 0.000 description 7
- 230000001568 sexual effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- 208000037009 Vaginitis bacterial Diseases 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 125000004122 cyclic group Chemical group 0.000 description 6
- 238000006073 displacement reaction Methods 0.000 description 6
- 150000002170 ethers Chemical class 0.000 description 6
- 239000011888 foil Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000004392 genitalia Anatomy 0.000 description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 6
- 230000007803 itching Effects 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 201000004801 prolapse of urethra Diseases 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 206010060800 Hot flush Diseases 0.000 description 5
- 241000186660 Lactobacillus Species 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 206010047786 Vulvovaginal discomfort Diseases 0.000 description 5
- 229940046836 anti-estrogen Drugs 0.000 description 5
- 230000001833 anti-estrogenic effect Effects 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 201000003146 cystitis Diseases 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000000328 estrogen antagonist Substances 0.000 description 5
- FEWJPZIEWOKRBE-LWMBPPNESA-N levotartaric acid Chemical class OC(=O)[C@@H](O)[C@H](O)C(O)=O FEWJPZIEWOKRBE-LWMBPPNESA-N 0.000 description 5
- 230000009247 menarche Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 230000035935 pregnancy Effects 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 206010046947 vaginismus Diseases 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- OEKMGABCSLYWOP-DHUJRADRSA-N [4-[(2s)-7-(2,2-dimethylpropanoyloxy)-4-methyl-2-[4-(2-piperidin-1-ylethoxy)phenyl]-2h-chromen-3-yl]phenyl] 2,2-dimethylpropanoate Chemical group C1=CC([C@H]2C(=C(C3=CC=C(OC(=O)C(C)(C)C)C=C3O2)C)C=2C=CC(OC(=O)C(C)(C)C)=CC=2)=CC=C1OCCN1CCCCC1 OEKMGABCSLYWOP-DHUJRADRSA-N 0.000 description 4
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 description 4
- DUYNJNWVGIWJRI-LJAQVGFWSA-N acolbifene Chemical compound C1=CC([C@H]2C(=C(C3=CC=C(O)C=C3O2)C)C=2C=CC(O)=CC=2)=CC=C1OCCN1CCCCC1 DUYNJNWVGIWJRI-LJAQVGFWSA-N 0.000 description 4
- 150000005215 alkyl ethers Chemical class 0.000 description 4
- 125000004429 atom Chemical group 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 229960000817 bazedoxifene Drugs 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000003679 cervix uteri Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 125000004663 dialkyl amino group Chemical group 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000000834 fixative Substances 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 230000003862 health status Effects 0.000 description 4
- 230000003054 hormonal effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000003387 muscular Effects 0.000 description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 229940095743 selective estrogen receptor modulator Drugs 0.000 description 4
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 4
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 229960001603 tamoxifen Drugs 0.000 description 4
- 239000006208 topical dosage form Substances 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 3
- 125000004070 6 membered heterocyclic group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 3
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- IUPVFHXEIGLEFF-UHFFFAOYSA-N [4-[2-(3-azabicyclo[2.2.1]heptan-3-yl)ethoxy]phenyl]-[6-hydroxy-2-(4-hydroxyphenyl)-1-benzothiophen-3-yl]methanone Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3C4CCC(C4)C3)=CC=2)C2=CC=C(O)C=C2S1 IUPVFHXEIGLEFF-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229950004203 droloxifene Drugs 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 230000001076 estrogenic effect Effects 0.000 description 3
- 150000004677 hydrates Chemical class 0.000 description 3
- 229950002248 idoxifene Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- GXESHMAMLJKROZ-IAPPQJPRSA-N lasofoxifene Chemical group C1([C@@H]2[C@@H](C3=CC=C(C=C3CC2)O)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 GXESHMAMLJKROZ-IAPPQJPRSA-N 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 125000001624 naphthyl group Chemical group 0.000 description 3
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 3
- 229960003327 ormeloxifene Drugs 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Chemical group 0.000 description 3
- 238000001139 pH measurement Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 208000013823 pelvic organ prolapse Diseases 0.000 description 3
- 210000004197 pelvis Anatomy 0.000 description 3
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 3
- 229960003387 progesterone Drugs 0.000 description 3
- 239000000186 progesterone Substances 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 210000003689 pubic bone Anatomy 0.000 description 3
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 3
- 229960004622 raloxifene Drugs 0.000 description 3
- 230000001850 reproductive effect Effects 0.000 description 3
- 210000005000 reproductive tract Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 3
- 229960005026 toremifene Drugs 0.000 description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 3
- 210000003708 urethra Anatomy 0.000 description 3
- 210000001635 urinary tract Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- SCVIEONTACSLJA-YGCRUXFTSA-N (e)-3-[4-[(e)-1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(\C=C\C(O)=O)=CC=1)/C1=CC=C(O)C=C1 SCVIEONTACSLJA-YGCRUXFTSA-N 0.000 description 2
- HJQQVNIORAQATK-DDJBQNAASA-N (e)-3-[4-[(z)-1,2-diphenylbut-1-enyl]phenyl]prop-2-enoic acid Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(\C=C\C(O)=O)=CC=1)/C1=CC=CC=C1 HJQQVNIORAQATK-DDJBQNAASA-N 0.000 description 2
- KJMFQJFNQYWQAV-UHFFFAOYSA-N 3h-imidazo[4,5-h]quinazoline Chemical class C1=NC=NC2=C(NC=N3)C3=CC=C21 KJMFQJFNQYWQAV-UHFFFAOYSA-N 0.000 description 2
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 2
- LDORHCBMWSQLIU-UHFFFAOYSA-N 6-phenyl-1h-pyrimidin-2-one Chemical class N1C(=O)N=CC=C1C1=CC=CC=C1 LDORHCBMWSQLIU-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000207201 Gardnerella vaginalis Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229920002527 Glycogen Polymers 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 241001313288 Labia Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 229940124639 Selective inhibitor Drugs 0.000 description 2
- 206010066218 Stress Urinary Incontinence Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Chemical group 0.000 description 2
- 208000000921 Urge Urinary Incontinence Diseases 0.000 description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 description 2
- 206010064899 Vulvovaginal mycotic infection Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 201000005661 acute cystitis Diseases 0.000 description 2
- 125000005042 acyloxymethyl group Chemical group 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 125000005206 alkoxycarbonyloxymethyl group Chemical group 0.000 description 2
- UPABQMWFWCMOFV-UHFFFAOYSA-N benethamine Chemical compound C=1C=CC=CC=1CNCCC1=CC=CC=C1 UPABQMWFWCMOFV-UHFFFAOYSA-N 0.000 description 2
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011111 cardboard Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 206010008323 cervicitis Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940096919 glycogen Drugs 0.000 description 2
- 238000002657 hormone replacement therapy Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000006194 liquid suspension Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 230000011599 ovarian follicle development Effects 0.000 description 2
- 230000016087 ovulation Effects 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 238000009595 pap smear Methods 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 230000037074 physically active Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003230 pyrimidines Chemical class 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- DRYRBWIFRVMRPV-UHFFFAOYSA-N quinazolin-4-amine Chemical class C1=CC=C2C(N)=NC=NC2=C1 DRYRBWIFRVMRPV-UHFFFAOYSA-N 0.000 description 2
- 150000003246 quinazolines Chemical class 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 201000010727 rectal prolapse Diseases 0.000 description 2
- 229960003310 sildenafil Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000002966 stenotic effect Effects 0.000 description 2
- 208000022170 stress incontinence Diseases 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229930192474 thiophene Natural products 0.000 description 2
- SMYMDRJWEFCCCI-UHFFFAOYSA-N trichloro(trichloromethoxy)methane Chemical compound ClC(Cl)(Cl)OC(Cl)(Cl)Cl SMYMDRJWEFCCCI-UHFFFAOYSA-N 0.000 description 2
- WZEOZJQLTRFNCU-UHFFFAOYSA-N trifluoro(trifluoromethoxy)methane Chemical compound FC(F)(F)OC(F)(F)F WZEOZJQLTRFNCU-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 208000000143 urethritis Diseases 0.000 description 2
- 206010046494 urge incontinence Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- TWHNMSJGYKMTRB-KXYUELECSA-N (2r,3r)-2,3-dihydroxybutanedioic acid;2-[(1r)-3-[di(propan-2-yl)amino]-1-phenylpropyl]-4-methylphenol Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 TWHNMSJGYKMTRB-KXYUELECSA-N 0.000 description 1
- IAPZXUKYTCQQFE-QZKDJMESSA-N (2r,3r,3as,5s)-2-(6-aminopurin-9-yl)-5-[carboxy(hydroxy)methyl]-3-hydroxy-3,3a-dihydro-2h-furo[3,2-b]furan-5-carboxylic acid Chemical class NC1=NC=NC2=C1N=CN2[C@H]1[C@H](O)[C@@H]2O[C@](C(O)=O)(C(O)C(O)=O)C=C2O1 IAPZXUKYTCQQFE-QZKDJMESSA-N 0.000 description 1
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 description 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- JWQYZECMEPOAPF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-ol Chemical compound C1=CC=C2CC(O)CCC2=C1 JWQYZECMEPOAPF-UHFFFAOYSA-N 0.000 description 1
- 125000005851 1-(N-(alkoxycarbonyl)amino)ethyl group Chemical group 0.000 description 1
- 125000005846 1-(alkanoyloxy)ethyl group Chemical group 0.000 description 1
- 125000005848 1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- 125000005847 1-methyl-1-(alkanoyloxy)-ethyl group Chemical group 0.000 description 1
- 125000005849 1-methyl-1-(alkoxycarbonyloxy)ethyl group Chemical group 0.000 description 1
- WJSVJNDMOQTICG-UHFFFAOYSA-N 2-amino-1-[(2-methyl-4-methylidene-5-oxooxolan-2-yl)methyl]-7h-purin-6-one Chemical compound NC1=NC=2N=CNC=2C(=O)N1CC1(C)CC(=C)C(=O)O1 WJSVJNDMOQTICG-UHFFFAOYSA-N 0.000 description 1
- HMBSMLATJKWAHH-UHFFFAOYSA-N 2-phenyl-1-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-3,4-dihydro-1h-isoquinolin-6-ol Chemical compound C1CC2=CC(O)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)N1C1=CC=CC=C1 HMBSMLATJKWAHH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QDPNAMRLQRQPMR-UHFFFAOYSA-N 3-ethyl-5-[5-(4-ethylpiperazin-1-yl)sulfonyl-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-ylmethyl)-4h-pyrazolo[4,3-d]pyrimidin-7-one Chemical compound C1CN(CC)CCN1S(=O)(=O)C1=CN=C(OCCOC)C(C=2NC(=O)C3=NN(CC=4N=CC=CC=4)C(CC)=C3N=2)=C1 QDPNAMRLQRQPMR-UHFFFAOYSA-N 0.000 description 1
- FLYJEBSUJDZJDE-UHFFFAOYSA-N 3-phenyl-1h-pyridin-2-one Chemical class O=C1NC=CC=C1C1=CC=CC=C1 FLYJEBSUJDZJDE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 150000005007 4-aminopyrimidines Chemical class 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- LINHQLFBBDHSEJ-UHFFFAOYSA-N 5h-pyrrolo[1,2-a]quinoxalin-4-one Chemical class O=C1NC2=CC=CC=C2N2C1=CC=C2 LINHQLFBBDHSEJ-UHFFFAOYSA-N 0.000 description 1
- SSQLMQBZAPRIRS-UHFFFAOYSA-N 6-(4-hydroxyphenyl)-5-[[4-(2-piperidin-1-ylethoxy)phenyl]methyl]naphthalen-2-ol Chemical compound C1=CC(O)=CC=C1C1=CC=C(C=C(O)C=C2)C2=C1CC(C=C1)=CC=C1OCCN1CCCCC1 SSQLMQBZAPRIRS-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 206010003439 Artificial menopause Diseases 0.000 description 1
- 208000004746 Atrophic Vaginitis Diseases 0.000 description 1
- 206010003693 Atrophic vulvovaginitis Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 206010006313 Breast tenderness Diseases 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 229910014585 C2-Ce Inorganic materials 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 208000034347 Faecal incontinence Diseases 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 241000207202 Gardnerella Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018168 Genital prolapse Diseases 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 241001313282 Labia minor Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053236 Mixed incontinence Diseases 0.000 description 1
- 125000005850 N-(alkoxycarbonyl)aminomethyl group Chemical group 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- SPRWZUVWSPGDJH-UHFFFAOYSA-N OC1=CC=C(C=C1)C=1C(=C2C=CC=CC2=CC1)CC1=CC=C(C=C1)OCCN1CCCCC1 Chemical compound OC1=CC=C(C=C1)C=1C(=C2C=CC=CC2=CC1)CC1=CC=C(C=C1)OCCN1CCCCC1 SPRWZUVWSPGDJH-UHFFFAOYSA-N 0.000 description 1
- 206010033165 Ovarian failure Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034268 Pelvic prolapse Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 102000004451 Pituitary Gonadotropins Human genes 0.000 description 1
- 108010081865 Pituitary Gonadotropins Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- 208000008718 Pyuria Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010050822 Suprapubic pain Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- IWEQQRMGNVVKQW-OQKDUQJOSA-N Toremifene citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 IWEQQRMGNVVKQW-OQKDUQJOSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 206010046542 Urinary hesitation Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 125000005251 aryl acyl group Chemical group 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 230000037358 bacterial metabolism Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Inorganic materials [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 239000000460 chlorine Chemical group 0.000 description 1
- 229910052801 chlorine Chemical group 0.000 description 1
- 125000004965 chloroalkyl group Chemical group 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 210000003029 clitoris Anatomy 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000001496 desquamative effect Effects 0.000 description 1
- 229940076405 detrol Drugs 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043237 diethanolamine Drugs 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- VFNGKCDDZUSWLR-UHFFFAOYSA-N disulfuric acid Chemical compound OS(=O)(=O)OS(O)(=O)=O VFNGKCDDZUSWLR-UHFFFAOYSA-N 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000011737 fluorine Chemical group 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 125000005643 gamma-butyrolacton-4-yl group Chemical group 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 150000002373 hemiacetals Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- HOFSPGAYXKNFAM-UHFFFAOYSA-N imidazo[4,5-f]quinoxalin-2-one Chemical class C1=CN=C2C3=NC(=O)N=C3C=CC2=N1 HOFSPGAYXKNFAM-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000030776 invasive breast carcinoma Diseases 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000029849 luteinization Effects 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000005858 morpholino(C2-C3)alkyl group Chemical group 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 201000004535 ovarian dysfunction Diseases 0.000 description 1
- 231100000539 ovarian failure Toxicity 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 238000012858 packaging process Methods 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 239000011087 paperboard Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000005856 piperidino(C2-C3)alkyl group Chemical group 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
- 201000010808 postmenopausal atrophic vaginitis Diseases 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000757 progestagenic effect Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JOZPEVMCAKXSEY-UHFFFAOYSA-N pyrimido[5,4-d]pyrimidine Chemical class N1=CN=CC2=NC=NC=C21 JOZPEVMCAKXSEY-UHFFFAOYSA-N 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 125000005857 pyrrolidino(C2-C3)alkyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- BKXVVCILCIUCLG-UHFFFAOYSA-N raloxifene hydrochloride Chemical compound [H+].[Cl-].C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 BKXVVCILCIUCLG-UHFFFAOYSA-N 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019980 sodium acid phosphate Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention relates to methods and kits useful for improving or maintaining urogenital health using an estrogen agonist/antagonist. The methods of treatment are effective for improving or maintaining urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
This invention also relates to methods of assessing vaginal health. Preferred estrogen agonists/antagonists are of the formula (I):
(see figure I) wherein A is CH2 or NR; B, D and E are CH or N; Y is an optionally substituted carbocyclic or heterocyclic group; Z1 is a hydrocarbon spacer optionally interrupted by a heteroatom; G is an amine group; R is H or alkyl; and a is 0, 1 or 2.
This invention also relates to methods of assessing vaginal health. Preferred estrogen agonists/antagonists are of the formula (I):
(see figure I) wherein A is CH2 or NR; B, D and E are CH or N; Y is an optionally substituted carbocyclic or heterocyclic group; Z1 is a hydrocarbon spacer optionally interrupted by a heteroatom; G is an amine group; R is H or alkyl; and a is 0, 1 or 2.
Description
r METHODS FOR ASSESSING, IMPROVING, OR MAINTAINING UROGENITAL
HEALTH IN POSTMENOPAUSAL WOMEN
This is a divisional application of Canadian patent application No. 2,358,938 filed October 12, 2001.
FIELD OF THE INVENTION
The present invention relates to drugs for improving or maintaining urogenital health using an estrogen agonist/antagonist. Tn postmenopausal women, conditions such as urinary and vaginal infections; incontinence; and vaginal dryness can be treated using the drugs of the present invention. The present invention also relates to methods of assessing vaginal health.
The subject matter of this divisional application is restricted to methods of assessing vaginal health in a patient.
It is to be understood that the expression "the present invention" or the like used in the specification of this application encompasses not only the subject matter of this divisional application, but that of the parent also.
BACKGROUND OF THE INVENTION
Menopause occurs naturally in women at an average age of 50 to 51 years in the United States. As ovaries age, response to pituitary gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) decreases, initially resulting in shorter follicular phases (thus, shorter menstrual cycles), fewer ovulations, decreased progesterone production, and more irregularity in menstrual cycles. Eventually, the follicle fails to respond and does not produce estrogen. The transitional phase, during which a woman passes out of the reproductive stage, begins before r -la-menopause. It is termed the climacteric or perimenopause, although many persons refer to it as menopause.
Premature menopause refers to ovarian failure of unknown cause that occurs before age 40. It may be associated with smoking, living at high altitude, or poor nutritional status. Artificial menopause may result from oophorectomy, chemotherapy, radiation of the pelvis, or any process that impairs ovarian blood supply or ovarian function.
Symptoms of the climacteric range from nonexistent to severe. Hot flushes (flashes) and sweating secondary to vasomotor instability affect 750 of women going through the perimenopausal period. Most have hot flushes for more than 1 year, and 25 to 50o for more than 5 years. The woman feels warm or hot and may perspire, sometimes profusely.
The skin, especially of the head and neck, becomes red and warm. The flush, which may last from 30 seconds to 5 minutes, may be followed by chills. Vasomotor symptoms of the hot flush coincide with the onset of LH pulses, but not every increase in LH is associated with a hot flush, suggesting that hypothalamic control of LH pulses is independent of that of flushes. This independence is confirmed by the occurrence of hot flushes in women who have had pituitary failure and do not secrete LH and/or FSH.
The large reduction in estrogen leads to profound changes in the lower genital tract; e.g., the vaginal mucosa and vulvar skin become thinner, the normal bacterial flora changes, and the labia minors, clitoris, uterus, and ovaries decrease in size. Inflammation of the vaginal mucosa (atrophic vaginitis) can cause the mucosa to have a strawberry appearance and can lead to urinary frequency and urgency, vaginal dryness, and dyspareunia. Women tend to lose pelvic muscle tone and to develop urinary incontinence, cystitis, and vaginitis.
Normal vaginal secretion is composed of vulvar secretions from sebaceous, sweat, Bartholin, and Skene glans; transudate from the vaginal wall;
exfoliated vaginal and cervical cells; cervical mucous; endometrial and oviductal fluids;
and microorganisms and their metabolic products. The type and amount of exfoliated cells, cervical mucous, and upper genital tract fluids are determined by the biochemical processes that are influenced by hormone levels (Huggins, G.R. and Preti, G. Clin Obstet Gynecol, 1981;24:355-377). The vaginal desquamative tissue is made up of vaginal epithelial cells that are responsive to varying amounts of estrogen and progesterone. Superficial cells, the predominant cell type in women of reproductive age, predominate when estrogen stimulation is present.
Intermediate cells predominate during the luteal phase because of progestogenic stimulation. Parabasal cells predominate in the absence of either hormone, a condition that may be found in postmenopausal women who are not receiving hormone replacement therapy.
The normal vaginal flora is predominately aerobic, with an average of six different species of bacteria, the most common of which is hydrogen peroxide producing lactobacilli. The microbiology of the vagina is determined by factors that affect the ability of bacteria to survive. These factors include vaginal pH
and the availability of glucose for bacterial metabolism. The premenopausal vagina is acidic, usually below a pH of 4.5. The environment is maintained by the presence of estrogen, which stimulates vaginal epithelial cells to produce glycogen, which can then be converted by lactobacilli to lactic acid. Lack of estrogenic stimulation of the vagina results in reduction in available glycogen and an increase in vaginal pH
resulting in a change in vaginal flora.
Bacterial vaginosis (BV) has previously been referred to as nonspecific vaginitis or Gardnerella vaginitis. It is an alteration of normal vaginal bacterial flora that results in the loss of hydrogen peroxide-producing lactobacilli and an overgrowth of predominately anaerobic bacteria (Eschenbach, D.A., et al., J
Clin Microbiol, 1989;27:251-256; Spiegel, C.A., et al., N Engl J Med, 1980;303:601-607).
The most common form of vaginitis in the United States is BV. Anaerobic bacteria can be found in less than 1 % of the flora of normal women. In women with BV, however, the concentration of anaerobes, as well as Gardnerella vaginalis and Mycopiasma hominis, is 100 to 1000 times higher than in normal women.
Lactobacilli are usually absent.
Numerous studies have shown an association of BV with significant adverse sequelae. Women with BV have an increased risk of pelvic inflammatory disease (PID) (Eschenbach, D.A., et al., Am J Obstet Gynecol, 1988;158:819-828), postoperative cuff infections after hysterectomy (Soper, D.E. et al., Am J
Obstet Gynecol, 1990;163:1016-1023), and abnormal cervical cytology (Platz-Christensen, J.J., et al., Acta Obstet Gynecol Scand, 1994;73:586-588).
Urinary tract infection in women may involve acute cystitis, recurrent cystitis, and urethritis. Women with acute cystitis generally have an abrupt onset of multiple, severe urinary tract symptoms including dysuria, frequency, and urgency associated with suprapubic or low back pain. Suprapubic tenderness may be noted on physical examination. Urinalysis reveals pyuria and sometimes hematuria.
About 20% of premenopausal women with an initial episode of cystitis will have recurrent infections. More that 90% of these recurrences are caused by exogenous reinfection. Postmenopausal women may also have frequent reinfections.
Hormonal replacement therapy or topically applied estrogen cream along with antimicrobial prophylaxis has been used in treating these patients. Women with dysuria caused by urethritis have a more gradual onset of mild symptoms, which may be associated with abnormal vaginal discharge or bleeding related to concurrent cervicitis. Patients may also experience lower abdominal pain.
Physical examination may reveal the presence of mucopurulent cervicitis.
Vaginal dryness in postmenopausal women is presumed to be caused by vaginal atrophy due to decreased estrogenic stimulation. When estrogen levels are low or absent, vascularity of the vagina is reduced and vaginal epithelium is thinned. The decrease in vascularity and vaginal epithelium results in less transudation and vaginal moisture.
, The genital and urinary tracts are intimately associated anatomically and embryologically from the earliest stages of their development. The bladder is located directly above the anterior vaginal wall and the urethra is fused to it. Both of these structures, as well as structures of the pelvic floor, are placed at risk during pregnancy and childbirth. In postmenopausal women, changes in the pelvic floor may occur due to changes in hormonal status that consequently result in incontinence, prolapse, and other disorders.
Each organ system in the pelvic floor, urinary, genital, and intestinal, traverses the pelvis and exits through its own orifice. Thus, these systems are intricately related in function and anatomic support (Wall, L.L. and DeLancey, J.O.L., Perspect Biol Med, 1991;34:486-496). Disorders of each of these components can necessarily have an impact on the functioning of the surrounding structures and the functional anatomy of the pelvic floor. The striated muscles of the pelvic floor, in combination with their fascial attachments, work together across the entire pelvis to prevent pelvic organ displacement, to maintain continence, and to control expulsive activities. Due to these complex interrelationships, each disturbance of pelvic support may be linked to problems in other organ systems.
Such is the case with incontinence disorders.
The nomenclature of the pelvic muscles has been subject to debate. The levator ani muscle (the broad general term for the muscles of the pelvic floor) has been described as consisting of a diaphragmatic portion (iliococcygeus) and the more important "pubovisceral" portion (Lawson, J.O. Ann R Col! Sur Engl 1974;54:244-252). The iliococcygeus or "diaphragmatic" portion of the levator ani consists of a thin muscular sheet that arises from the pelvic sidewall on either side of the arcus tendinous and ischial spine and inserts into a midline raphe behind the rectum. The pubovisceral ("pubococcygeus") portion of the levator ani muscle consists of a thick U-shaped band of muscle arising from the pubic bone and attaching to the lateral walls of the vagina and rectum. Therefore, the rectum is supported by a muscular sling that pulls it toward the pubic bones when the muscles contract. The muscular band is often called the puborectalis or the pubococcygeus muscle or the pubovisceral muscle. When the pubovisceral contracts, it pulls the rectum, vagina, and urethra anteriorly toward the pubic bone and constricts the lumen of these pelvic organs. It is this contractile property that is so important in maintaining urinary and fecal continence and in providing support of ' ., the genital organs (vagina, cervix, uterus) that lie upon and are supported by the levator plate.
Connective tissue is composed primarily of elastin and collagen fibers in a polysaccharide ground substance. The composition of connective tissue is not constant but varies in different sites throughout the body. Connective tissue forms capsules to help maintain the structural integrity of the organs. If connective tissue fails, muscular support will be weak. Connective tissue is not static but instead is a dynamic tissue that undergoes constant turnover and remodeling. Hormonal changes have significant effects on collagen which is thus related to aging and the postmenopausal state (Brincat, M. et al., Obstet Gynecol, 1987;70:123-127;
Castelo-Branco, C. ef al., Maturitas, 1992;15:113-119). Connective tissue abnormalities are a significant factor contributing to prolapse and related conditions such as urinary and fecal incontinence.
In premenopausal women, 173-estradiol produced by the ovaries is the chief active circulating estrogen. Serum estradiol concentrations are low in preadolescent girls and increase at menarche. In women, they range from about 100 pg per milliliter (367 pmol per liter) in the follicular phase to about 600 pg per milliliter (2200 pmol per liter) at the time of ovulation. They may rise to nearly 20,000 pg per milliliter (70,000 pmol per liter) during pregnancy. After menopause, serum estradiol concentrations fall to values similar to or lower than those in men of similar age (5 to 20 pg per milliliter [18 to 74 pmol per liter]) (Yen, S.S.C.
and Jaffe, R.B., eds. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 3rd ed. Philadelphia: W.B. Saunders, (1991)).
The effects of estrogen on urogenital health and tone are generally positive, however, some of the non-urogenital effects of estrogen, such as increased risk of breast cancer or the occurrence of blood clots may offset its beneficial efFects.
Breast cancer is typically or often a hormone-dependent disease. Women without functioning ovaries who never receive estrogen replacement rarely develop breast cancer. The female-to-male ratio for the disease is about 150 to 1.
Findings indicate that hormones play a critical role as promoters of the disease. For most epithelial malignancies, a log-log plot of incidence versus age shows a straight-line increase with every year of life. A similar plot for breast cancer shows the same straight line increase, but with a decrease in slope beginning at the age of menopause. The three dates in a woman's life that have a major impact on breast ~ ., cancer incidence are age of menarche, age at first full-term pregnancy, and age of menopause. Women who experience menarche at age 16 have only 50 to 60 percent of the lifetime breast cancer risk of women who experience menarche at age 12. Similarly, menopause occurring 10 years before the median age (52 years), whether natural or surgically induced, reduces lifetime breast cancer risk by about 35 percent. Compared with nulliparous women, women who have a first full-term pregnancy by age 18 have 30 to 40 percent the risk of breast cancer. Thus, length of menstrual life -particularly the fraction occurring before the first full-term pregnancy - is a substantial component of the total risk of breast cancer. This factor can account for 70 to 80 percent of the variation in breast cancer frequency in different countries.
International variation has provided some of the most important clues on hormonal carcinogenesis. A woman living to age 80 in North America has 1 chance in 9 of developing invasive breast cancer. Asian women have one-fifth to one-tenth the risk of breast cancer of women in North America or Western Europe. Asian women have substantially lower concentrations of estrogens and progesterone. These differences cannot be explained on a genetic basis, because Asian women living in a Western environment have a risk identical to that of their Western counterparts. These women also differ markedly in height and weight from Asian women in Asia; height and weight are critical regulators of age of menarche and have substantial effects on plasma concentrations of estrogens. (Lippman, M.E., Breast Cancer, Chapter 91, in Harrison's Principles of Internal Medicine, 14th ed. , 1998) .
' s -6a-Labrie (WO 01/54699, Endorecherche Inc) discusses the use of a combination of a Selective Estrogen Receptor Modulator (SERM) and an estrogen for the reduction or elimination of menopausal symptoms. Lee et al.
(EP-A-1 149 579, Pfizer Products Inc) discuss the use of an estrogen agonist/antagonist for the treatment of female sexual dysfunction. MacClean and Thompson (EP-A-0 792 641, Pfizer Inc) discuss the use of an estrogen agonist/antagonist for the treatment of a number of pathological conditions.
SUN~1ARY OF THE INVENTION
The present invention provides drugs for improving or maintaining urogenital health comprising a therapeutically effective amount of an estrogen agonist/antagonist.
The term "drug" in this specification should be understood to mean a pharmaceutical composition or formulation containing at least one pharmaceutically acceptable carrier, diluent or excipient.
In a preferred embodiment, the patient is a postmenopausal woman.
In another preferred embodiment, the estrogen agonist/antagonist is a compound of formula (I):
_7-Z~-G
E ~D
Y (I) B/
Ho A
wherein:
A is selected from CHZ and NR;
B, D and E are independently selected from CH and N;
Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;
(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;
(c) C3-C$ cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;
(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)", optionally substituted with 1-3 substituents independently selected from R4;
(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)"
optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to iwo heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)S-, optionally substituted with 1-3 substituents independently selected from R4;
-$-Z' IS
(a) -(CH2)p W(CH2)q-(b) -O(CH2)P CR5R6-;
(c) -O(CHZ)PW(CHZ)q ;
(d) -OCHR2CHR3-;
or (e) -SCHR2CHR3-;
G is (a) -NR'RS;
(CH2)m~ 2 N Z
~(CH2)n~
(b) wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CHZ-;
optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or N
-OCH2 ()n .
Z' and G in combination may be W is (a) -CH2-;
(b) -CH=CH-;
(c) -O-;
(d) -NRZ-;
(e) 'S(~)n'~
O
(f) -C- ;
(g) -CRZ(OH)-;
-g_ (h) -CONRZ-;
(i) -NR2C0-;
(j) ; or (k) -C---C-;
R is hydrogen or C,-C6 alkyl;
RZ and R3 are independently (a) hydrogen; or (b) C,-C4 alkyl;
R4 is (a) hydrogen;
(b) halogen;
(c) C,-C6 alkyl;
(d) C,-C4 alkoxy;
(e) C,-C4 acyloxy;
(f) C,-C4 alkylthio;
(g) C,-C4 alkylsulfinyl;
(h) C,-C4 alkylsulfonyl;
(i) hydroxy (C,-C4)aikyl;
lj) aryl (C,-C4)alkyl;
(k) -C02H;
(I) -CN;
(m) -CONHOR;
(n) -S02NHR;
(o) -NH2;
(p) C,-C4 alkylamino;
(q) C,-C4 dialkylamino;
(r) -NHSOZR;
(s) -N02;
(t) -aryl; or (u) -OH;
R5 and R6 are independently C,-C8 alkyl or together form a C3-C,o carbocyclic ring;
R' and R$ are independently (a) phenyl;
(b) a C3-Coo carbocyclic ring, saturated or unsaturated;
(c) a C3-C,o heterocyclic ring containing' up to two heteroatoms, selected from -O-, -N- and -S-;
(d) H;
(e) C,-Cs alkyl; or (f) form a 3 to 8 membered nitrogen containing ring with R5 or Rg R' and R8 in either linear or ring fom~ may optionally be substituted with up to three substituents independently selected from C,-Cs alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R' and R8 may be optionally fused to a phenyl ring;
a is 0, 1 or 2;
m is 1, 2 or 3;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
In another preferred embodiment, the estrogen agonist antagonist is a compound of formula (IA) OCH~CH~G
R°
HG
(IA) wherein G is -N I , or -N
!!I /N
R4 is H, OH, F, or CI; and B and E are independently selected from CH
and N.or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In a preferred embodiment, the estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In another preferred embodiment, the estrogen agonist antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, D-tartrate salt.
In another prefer-ed embodiment, the estrogen agonist antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)'benzyl]-naphthalen-2-ol, (4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW
7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:
(V) O
~(CHy)s ~ t Xp R3B
RIB
RaB
N
RzB
A
(VI) wherein:
R,e is selected from H, OH, -O-C(O~C,-C,2 alkyl (straight chain or branched), -O-C,-C,2 alkyl (straight chain or branched or cyclic), or halogens or C,-Ca halogenated ethers, R28, R3g, R4B, RSB, and RsB are independently selected from H, OH, -O-C(O)-C,-C,2 (straight chain or branched), -O-C,-C,2 (straight chain or branched or cyclic), halogens, or C,-C4 halogenated ethers, cyano, C,-Cg alkyl (straight chain or branched), or trifluoromethyl;
Xp is selected from H, C,-Cg alkyl, cyano, vitro, trifluoromethyl, and halogen;
s is 2 or 3;
Yp is the moiety:
~ /R,B
N
RaB
wherein:
a) R,e and ReB are independently selected from the group of H, C,-Cs alkyl, or phenyl optionally substituted by CN, C,-Cs alkyl (straight chain or branched), C,-Ce alkoxy (straight chain or branched), halogen, -OH, -CF3, or -OCF3; or b) R,B and R8B are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-CQ alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR,e, -NHz, -NH(C~-C4 alkyl), -N(C~-C4 alkyl)2, -NHS02R,B, -NHCOR,B, -NOZ, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or c) R,B and R8B are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR~B, -NH2, -NH(C,-C4 alkyl), -N(C~-C4 alkyl)Z, -NHS02R,g, -NHCOR~B, -N02, or phenyl optionally substituted with 1-3 (C~-C4)alkyl; or d) R,e and R8B are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C~-C4)alkyl, -C02H, -CN, -CONHR,e, -NH2, -NH(C~-CQ alkyl), -N(C~-C4 alkyl)2, -NHS02 R,B, NHCOR,B -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or e) Rye and R8B are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C~-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,e, -NH2, -NH(C,-C4 alkyl), -N(C1-C4 alkyl)2, -NHSOZR,B, -NHCOR,e, -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or f) Rye and RgB are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-Cg alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C~-C4 alkylsulfonyl, hydroxy (C, -C4)alkyl, -C02 H, -CN, -CONHR,B, -NH2, -NH(C~-C4 alkyl), -N(C,-C4 alkyl)2, -NHSOZR,e, -NHCOR~B, -N02, or phenyl optionally substituted with 1-3 (C~-C4) alkyl; or an optical or geometric isomer thereof;
or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound, TSE-424, of formula Va below:
H
(Va) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound EM-652 of formula III below or is EM-800 of formula IV below:
' H
O
C
..
(IV) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
Also provided are drugs for lowering vaginal pH; treating urinary tract infections; treating vaginal dryness; treating vaginal itching; treating undesired vaginal spasms; treating vaginitis; treating vaginal yeast or bacterial infections;
treating vulvar atrophy; treating cystocele, urethocele, rectocele or enterocele prolapse;
treating urinary and anal incontinence; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms, which comprises a therapeutically effective amount of an estrogen agonist~./antagonist.
In a preferred embodiment of the drugs, the patient is a postmenopausal woman.
In another prefer-ed embodiment of the drugs, the estrogen agonist /
antagonist is a compound of formula (I):
' /Y (I) ~B
HO
()e A
wherein:
A is selected from CH2 and NR;
B, D and E are independently selected from CH and N;
Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;
(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;
(c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;
Z'-G
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;
(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)S , optionally substituted with 1-3 substituents independently selected from R4;
(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)S
optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)S , optionally substituted with 1-3 substituents independently selected from R4;
Z' is (a) -(CH2)p W(CH2)q ;
(b) -O(CH2)p CRSRg-;
(c) -O(CHZ)pW(CH2)a-;
(d) -OCHR2CHR3-;
or (e) -SCHR2CHR3-;
G is (a) -NR'R8;
N / (CH2)m~Z2 ~(CH2)n~
(b) wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CHZ-;
optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or Z' and G in combination may be N
-OCH2 ()n W IS
(a) -CHZ-;
(b) -CH=CH-;
(c) -O-;
(d) -NR2-;
(e) -S(O)S ;
O
(f) -C- ;
(g) -CRZ(OH)-;
(h) -CONR2-;
(i) -NRZCO-;
G) ; or (k) -C---C-;
R is hydrogen or C,-C6 alkyl;
R2 and R3 are independently (a) hydrogen; or (b) C,-C4 alkyl;
R4 is (a) hydrogen;
(b) halogen;
(c) C,-C6 alkyl;
(d) C,-C4 alkoxy;
(e) C,-C4 acyloxy;
(f) C,-C4 alkylthio;
(g) C,-C4 alkylsulfinyl;
(h) C,-C4 alkylsulfonyl;
(i) hydroxy (C,-C4)alkyl;
(j) aryl (C,-C4)alkyl;
(k) -COZH;
' 72222-474 (I) -CN;
(m) -CONHOR;
(n) -SOZNHR;
(o) -NH2;
(p) C,-C4 alkylamino;
(q) C~-C4 dialkylamino;
(r) -NHSOZR;
(s) -NO2;
(t) -aryl; or (u) -OH;
RS and Rs are independently C,-C8 alkyl or together form a C3-C,o carbocyclic ring;
R' and R8 are independently (a) phenyl;
(b) a C3-C,o carbocyclic ring, saturated or unsaturated;
(c) a C3-Coo heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-;
(d) H;
(e) C,-Cs alkyl; or (f) form a 3 to 8 membered nitrogen containing ring with R5 or Rs.
R' and R$ in either linear or ring form may optionally be substituted with up to three substituents independently selected from C~-Cs alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R' and R8 may be optionally fused to a phenyl ring;
a is 0, 1 or 2;
m is 1, 2 or 3;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
In another preferred embodiment of the drugs the estrogen agonist /
antagonist is a compound of formula (IA) a . 172222-474 OCH~CH~G
R.
HG
(IA) wherein G is -N I or -N
N
R4 is H, OH, F, or CI; and B and E are independently selected from CH
and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In a preferred embodiment of the drugs the estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In another preferred embodiment of the drugs the estrogen agonist /
antagonist is the (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8 tetrahydro-naphthalene-2-ol, D-tartrate salt.
In another preferred embodiment of the drugs the estrogen agonist antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-(6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW
7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:
Xq R38 RIB
\ R4B N) N \
RzB
A
RIB \
RaB
N \
R2e wherein:
A
(VI) RIB is selected from H, OH, -O-C(O)-C,-C~2 alkyl (straight chain or branched), -O-C~-C,2 alkyl (straight chain or branched or cyclic), or halogens or C,-C4 halogenated ethers, RZB, R3B, R4B, R5B, and ReB are independently selected from H, OH, -O-C(O~
C,-C,z (straight chain or branched), -O-C,-C,2 (straight chain or branched or cyclic), halogens, or C,-C4 halogenated ethers, cyano, C~-Cg alkyl (straight chain or branched), or trifluoromethyl;
XA is selected from H, C~-C6 alkyl, cyano, vitro, trifluoromethyl, and halogen;
sis2or3;
YA is the moiety:
\ iR~B
N
RBB
wherein:
a) RIB and R8B are independently selected from the group of H, C,-Ce alkyl, or phenyl optionally substituted by CN, C,-C6 alkyl (straight chain or branched), C,-C6 alkoxy (straight chain or branched), halogen, -OH, -CF3, or -OCF3; or b) RIB and R8g are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroa#om, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,B, -NHZ, -NH(C,-C4 alkyl), -N(C,-C4 alkyl)2, -NHS02R,B, -NHCOR,B, -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or c) RIB and R8B are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,e, -NH2, -NH(C,-C4 alkyl), -N(C,-C4 alkyl)2, -NHS02R,B, -NHCOR,B, -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or d) RIB and R88 are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-CQ alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,B, -NH2, -NH(C,-C4 alkyl), -N(C,-C4 alkyl)2, -NHS02 R,B, -NHCOR,e -NO2, or phenyl optionally substituted with 1-3 (C,-CQ)alkyl; or e) RIB and R8B are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-CQ alkoxy, trihalomethoxy, C,-acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR~B, -NH2, -NH(Ci-C4 alkyl), -N(C1-C4 alkyl)2, -NHSOZR,B, -NHCOR,e, -NOZ, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or f) R,B and R$B are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C~-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C~-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C, -C4)alkyl, -COZ H, -CN, -CONHR,B, -NH2, -NH(C~-C4 alkyl), -N(C~-CQ alkyl)2, -NHS02R,g, -NHCOR~B, -NO2, or phenyl optionally substituted with 1-3 (C~-C4) alkyl; or an optical or geometric isomer thereof;
or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound, TSE-424, of formula Va below:
H
(Va) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound EM-652 of formula III below or is EM-800 of formula IV below:
(III) O
C
N
O ~ ,., ~CH3 (IV) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
Also provided by the present invention are kits for use by a consumer to improve or maintain urogenital health comprising:
~
, (a) a pharmaceutical composition comprising an estrogen agonist/antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and (b) a written matter describing indications or instructions for use of the pharmaceutical composition to improve or maintain urogenital health; lower vaginal pH;
treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis; treat vaginal yeast or bacterial infections;
treat vulvar atrophy; treat cystocele, urethrocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency;
or increase the frequency or intensity, of orgasms.
In another embodiment of the kits, an additional compound useful to improve or maintain urogenital health;
lower vaginal pH; treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis~ treat vaginal yeast or bacterial infections; treat vulvar atrophy; treat cystocele, urethrocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency; or increase the frequency or intensity of orgasms is included in the kit.
The present invention also provides a use of an estrogen agonist/antagonist for lowering vaginal pH;
treating vaginitis; treating a vaginal yeast or bacterial infection; treating vulvar atrophy; treating urethrocele, cystocele, rectocele, or enterocele prolapse; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms in a female patient.
The present invention also provides a use of an estrogen agonist/antagonist for the manufacture of a -25a-medicament for lowering vaginal pH; treating vaginitis:
treating a vaginal yeast or bacterial infection; treating vulvar atrophy; treating urethrocele, cystocele, rectocele, or enterocele prolapse; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms in a female patient.
Also provided are methods for assessing vaginal health in a patient, the methods comprising:
a) conducting a gynecological examination;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index;
d) determining vaginal prolapse;
e) administering a questionnaire to the patient; and f) measuring plasma hormone levels, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
In a preferred embodiment of the methods, the gynecological examination comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length.
In another preferred embodiment of the methods, the gynecological exam further comprises an assessment of the quantity of pubic hair and the thickness of the vulva:
In another preferred embodiment of the methods, the plasma hormone levels that are measured include estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione.
In another preferred embodiment of the methods, vaginal prolapse is determined by grading the prolapse using the following scale:
Grade normal position inside the mid-vaginal axis for 0 anterior posterior wall prolapse and above the ischial spines for cervical or vaginal cuff. By definition, the most apical point is -3 cm superior to the hymen.
Grade if the prolapse crosses the respective thresholds 1 and descends halfway to the hymen Grade descent,to the hymen Grade descent 2 cm beyond the hymen Grade maximum possible descent for each site. A complete 4 eversion is about 5 cm beyond hymen.
In another preferred embodiment of the methods, the questionnaire comprises questions relating to:
1 ) the number of vaginal infections;
2) the number of urinary infections;
HEALTH IN POSTMENOPAUSAL WOMEN
This is a divisional application of Canadian patent application No. 2,358,938 filed October 12, 2001.
FIELD OF THE INVENTION
The present invention relates to drugs for improving or maintaining urogenital health using an estrogen agonist/antagonist. Tn postmenopausal women, conditions such as urinary and vaginal infections; incontinence; and vaginal dryness can be treated using the drugs of the present invention. The present invention also relates to methods of assessing vaginal health.
The subject matter of this divisional application is restricted to methods of assessing vaginal health in a patient.
It is to be understood that the expression "the present invention" or the like used in the specification of this application encompasses not only the subject matter of this divisional application, but that of the parent also.
BACKGROUND OF THE INVENTION
Menopause occurs naturally in women at an average age of 50 to 51 years in the United States. As ovaries age, response to pituitary gonadotropins (follicle-stimulating hormone [FSH] and luteinizing hormone [LH]) decreases, initially resulting in shorter follicular phases (thus, shorter menstrual cycles), fewer ovulations, decreased progesterone production, and more irregularity in menstrual cycles. Eventually, the follicle fails to respond and does not produce estrogen. The transitional phase, during which a woman passes out of the reproductive stage, begins before r -la-menopause. It is termed the climacteric or perimenopause, although many persons refer to it as menopause.
Premature menopause refers to ovarian failure of unknown cause that occurs before age 40. It may be associated with smoking, living at high altitude, or poor nutritional status. Artificial menopause may result from oophorectomy, chemotherapy, radiation of the pelvis, or any process that impairs ovarian blood supply or ovarian function.
Symptoms of the climacteric range from nonexistent to severe. Hot flushes (flashes) and sweating secondary to vasomotor instability affect 750 of women going through the perimenopausal period. Most have hot flushes for more than 1 year, and 25 to 50o for more than 5 years. The woman feels warm or hot and may perspire, sometimes profusely.
The skin, especially of the head and neck, becomes red and warm. The flush, which may last from 30 seconds to 5 minutes, may be followed by chills. Vasomotor symptoms of the hot flush coincide with the onset of LH pulses, but not every increase in LH is associated with a hot flush, suggesting that hypothalamic control of LH pulses is independent of that of flushes. This independence is confirmed by the occurrence of hot flushes in women who have had pituitary failure and do not secrete LH and/or FSH.
The large reduction in estrogen leads to profound changes in the lower genital tract; e.g., the vaginal mucosa and vulvar skin become thinner, the normal bacterial flora changes, and the labia minors, clitoris, uterus, and ovaries decrease in size. Inflammation of the vaginal mucosa (atrophic vaginitis) can cause the mucosa to have a strawberry appearance and can lead to urinary frequency and urgency, vaginal dryness, and dyspareunia. Women tend to lose pelvic muscle tone and to develop urinary incontinence, cystitis, and vaginitis.
Normal vaginal secretion is composed of vulvar secretions from sebaceous, sweat, Bartholin, and Skene glans; transudate from the vaginal wall;
exfoliated vaginal and cervical cells; cervical mucous; endometrial and oviductal fluids;
and microorganisms and their metabolic products. The type and amount of exfoliated cells, cervical mucous, and upper genital tract fluids are determined by the biochemical processes that are influenced by hormone levels (Huggins, G.R. and Preti, G. Clin Obstet Gynecol, 1981;24:355-377). The vaginal desquamative tissue is made up of vaginal epithelial cells that are responsive to varying amounts of estrogen and progesterone. Superficial cells, the predominant cell type in women of reproductive age, predominate when estrogen stimulation is present.
Intermediate cells predominate during the luteal phase because of progestogenic stimulation. Parabasal cells predominate in the absence of either hormone, a condition that may be found in postmenopausal women who are not receiving hormone replacement therapy.
The normal vaginal flora is predominately aerobic, with an average of six different species of bacteria, the most common of which is hydrogen peroxide producing lactobacilli. The microbiology of the vagina is determined by factors that affect the ability of bacteria to survive. These factors include vaginal pH
and the availability of glucose for bacterial metabolism. The premenopausal vagina is acidic, usually below a pH of 4.5. The environment is maintained by the presence of estrogen, which stimulates vaginal epithelial cells to produce glycogen, which can then be converted by lactobacilli to lactic acid. Lack of estrogenic stimulation of the vagina results in reduction in available glycogen and an increase in vaginal pH
resulting in a change in vaginal flora.
Bacterial vaginosis (BV) has previously been referred to as nonspecific vaginitis or Gardnerella vaginitis. It is an alteration of normal vaginal bacterial flora that results in the loss of hydrogen peroxide-producing lactobacilli and an overgrowth of predominately anaerobic bacteria (Eschenbach, D.A., et al., J
Clin Microbiol, 1989;27:251-256; Spiegel, C.A., et al., N Engl J Med, 1980;303:601-607).
The most common form of vaginitis in the United States is BV. Anaerobic bacteria can be found in less than 1 % of the flora of normal women. In women with BV, however, the concentration of anaerobes, as well as Gardnerella vaginalis and Mycopiasma hominis, is 100 to 1000 times higher than in normal women.
Lactobacilli are usually absent.
Numerous studies have shown an association of BV with significant adverse sequelae. Women with BV have an increased risk of pelvic inflammatory disease (PID) (Eschenbach, D.A., et al., Am J Obstet Gynecol, 1988;158:819-828), postoperative cuff infections after hysterectomy (Soper, D.E. et al., Am J
Obstet Gynecol, 1990;163:1016-1023), and abnormal cervical cytology (Platz-Christensen, J.J., et al., Acta Obstet Gynecol Scand, 1994;73:586-588).
Urinary tract infection in women may involve acute cystitis, recurrent cystitis, and urethritis. Women with acute cystitis generally have an abrupt onset of multiple, severe urinary tract symptoms including dysuria, frequency, and urgency associated with suprapubic or low back pain. Suprapubic tenderness may be noted on physical examination. Urinalysis reveals pyuria and sometimes hematuria.
About 20% of premenopausal women with an initial episode of cystitis will have recurrent infections. More that 90% of these recurrences are caused by exogenous reinfection. Postmenopausal women may also have frequent reinfections.
Hormonal replacement therapy or topically applied estrogen cream along with antimicrobial prophylaxis has been used in treating these patients. Women with dysuria caused by urethritis have a more gradual onset of mild symptoms, which may be associated with abnormal vaginal discharge or bleeding related to concurrent cervicitis. Patients may also experience lower abdominal pain.
Physical examination may reveal the presence of mucopurulent cervicitis.
Vaginal dryness in postmenopausal women is presumed to be caused by vaginal atrophy due to decreased estrogenic stimulation. When estrogen levels are low or absent, vascularity of the vagina is reduced and vaginal epithelium is thinned. The decrease in vascularity and vaginal epithelium results in less transudation and vaginal moisture.
, The genital and urinary tracts are intimately associated anatomically and embryologically from the earliest stages of their development. The bladder is located directly above the anterior vaginal wall and the urethra is fused to it. Both of these structures, as well as structures of the pelvic floor, are placed at risk during pregnancy and childbirth. In postmenopausal women, changes in the pelvic floor may occur due to changes in hormonal status that consequently result in incontinence, prolapse, and other disorders.
Each organ system in the pelvic floor, urinary, genital, and intestinal, traverses the pelvis and exits through its own orifice. Thus, these systems are intricately related in function and anatomic support (Wall, L.L. and DeLancey, J.O.L., Perspect Biol Med, 1991;34:486-496). Disorders of each of these components can necessarily have an impact on the functioning of the surrounding structures and the functional anatomy of the pelvic floor. The striated muscles of the pelvic floor, in combination with their fascial attachments, work together across the entire pelvis to prevent pelvic organ displacement, to maintain continence, and to control expulsive activities. Due to these complex interrelationships, each disturbance of pelvic support may be linked to problems in other organ systems.
Such is the case with incontinence disorders.
The nomenclature of the pelvic muscles has been subject to debate. The levator ani muscle (the broad general term for the muscles of the pelvic floor) has been described as consisting of a diaphragmatic portion (iliococcygeus) and the more important "pubovisceral" portion (Lawson, J.O. Ann R Col! Sur Engl 1974;54:244-252). The iliococcygeus or "diaphragmatic" portion of the levator ani consists of a thin muscular sheet that arises from the pelvic sidewall on either side of the arcus tendinous and ischial spine and inserts into a midline raphe behind the rectum. The pubovisceral ("pubococcygeus") portion of the levator ani muscle consists of a thick U-shaped band of muscle arising from the pubic bone and attaching to the lateral walls of the vagina and rectum. Therefore, the rectum is supported by a muscular sling that pulls it toward the pubic bones when the muscles contract. The muscular band is often called the puborectalis or the pubococcygeus muscle or the pubovisceral muscle. When the pubovisceral contracts, it pulls the rectum, vagina, and urethra anteriorly toward the pubic bone and constricts the lumen of these pelvic organs. It is this contractile property that is so important in maintaining urinary and fecal continence and in providing support of ' ., the genital organs (vagina, cervix, uterus) that lie upon and are supported by the levator plate.
Connective tissue is composed primarily of elastin and collagen fibers in a polysaccharide ground substance. The composition of connective tissue is not constant but varies in different sites throughout the body. Connective tissue forms capsules to help maintain the structural integrity of the organs. If connective tissue fails, muscular support will be weak. Connective tissue is not static but instead is a dynamic tissue that undergoes constant turnover and remodeling. Hormonal changes have significant effects on collagen which is thus related to aging and the postmenopausal state (Brincat, M. et al., Obstet Gynecol, 1987;70:123-127;
Castelo-Branco, C. ef al., Maturitas, 1992;15:113-119). Connective tissue abnormalities are a significant factor contributing to prolapse and related conditions such as urinary and fecal incontinence.
In premenopausal women, 173-estradiol produced by the ovaries is the chief active circulating estrogen. Serum estradiol concentrations are low in preadolescent girls and increase at menarche. In women, they range from about 100 pg per milliliter (367 pmol per liter) in the follicular phase to about 600 pg per milliliter (2200 pmol per liter) at the time of ovulation. They may rise to nearly 20,000 pg per milliliter (70,000 pmol per liter) during pregnancy. After menopause, serum estradiol concentrations fall to values similar to or lower than those in men of similar age (5 to 20 pg per milliliter [18 to 74 pmol per liter]) (Yen, S.S.C.
and Jaffe, R.B., eds. Reproductive Endocrinology: Physiology, Pathophysiology and Clinical Management, 3rd ed. Philadelphia: W.B. Saunders, (1991)).
The effects of estrogen on urogenital health and tone are generally positive, however, some of the non-urogenital effects of estrogen, such as increased risk of breast cancer or the occurrence of blood clots may offset its beneficial efFects.
Breast cancer is typically or often a hormone-dependent disease. Women without functioning ovaries who never receive estrogen replacement rarely develop breast cancer. The female-to-male ratio for the disease is about 150 to 1.
Findings indicate that hormones play a critical role as promoters of the disease. For most epithelial malignancies, a log-log plot of incidence versus age shows a straight-line increase with every year of life. A similar plot for breast cancer shows the same straight line increase, but with a decrease in slope beginning at the age of menopause. The three dates in a woman's life that have a major impact on breast ~ ., cancer incidence are age of menarche, age at first full-term pregnancy, and age of menopause. Women who experience menarche at age 16 have only 50 to 60 percent of the lifetime breast cancer risk of women who experience menarche at age 12. Similarly, menopause occurring 10 years before the median age (52 years), whether natural or surgically induced, reduces lifetime breast cancer risk by about 35 percent. Compared with nulliparous women, women who have a first full-term pregnancy by age 18 have 30 to 40 percent the risk of breast cancer. Thus, length of menstrual life -particularly the fraction occurring before the first full-term pregnancy - is a substantial component of the total risk of breast cancer. This factor can account for 70 to 80 percent of the variation in breast cancer frequency in different countries.
International variation has provided some of the most important clues on hormonal carcinogenesis. A woman living to age 80 in North America has 1 chance in 9 of developing invasive breast cancer. Asian women have one-fifth to one-tenth the risk of breast cancer of women in North America or Western Europe. Asian women have substantially lower concentrations of estrogens and progesterone. These differences cannot be explained on a genetic basis, because Asian women living in a Western environment have a risk identical to that of their Western counterparts. These women also differ markedly in height and weight from Asian women in Asia; height and weight are critical regulators of age of menarche and have substantial effects on plasma concentrations of estrogens. (Lippman, M.E., Breast Cancer, Chapter 91, in Harrison's Principles of Internal Medicine, 14th ed. , 1998) .
' s -6a-Labrie (WO 01/54699, Endorecherche Inc) discusses the use of a combination of a Selective Estrogen Receptor Modulator (SERM) and an estrogen for the reduction or elimination of menopausal symptoms. Lee et al.
(EP-A-1 149 579, Pfizer Products Inc) discuss the use of an estrogen agonist/antagonist for the treatment of female sexual dysfunction. MacClean and Thompson (EP-A-0 792 641, Pfizer Inc) discuss the use of an estrogen agonist/antagonist for the treatment of a number of pathological conditions.
SUN~1ARY OF THE INVENTION
The present invention provides drugs for improving or maintaining urogenital health comprising a therapeutically effective amount of an estrogen agonist/antagonist.
The term "drug" in this specification should be understood to mean a pharmaceutical composition or formulation containing at least one pharmaceutically acceptable carrier, diluent or excipient.
In a preferred embodiment, the patient is a postmenopausal woman.
In another preferred embodiment, the estrogen agonist/antagonist is a compound of formula (I):
_7-Z~-G
E ~D
Y (I) B/
Ho A
wherein:
A is selected from CHZ and NR;
B, D and E are independently selected from CH and N;
Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;
(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;
(c) C3-C$ cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;
(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)", optionally substituted with 1-3 substituents independently selected from R4;
(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)"
optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to iwo heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)S-, optionally substituted with 1-3 substituents independently selected from R4;
-$-Z' IS
(a) -(CH2)p W(CH2)q-(b) -O(CH2)P CR5R6-;
(c) -O(CHZ)PW(CHZ)q ;
(d) -OCHR2CHR3-;
or (e) -SCHR2CHR3-;
G is (a) -NR'RS;
(CH2)m~ 2 N Z
~(CH2)n~
(b) wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CHZ-;
optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or N
-OCH2 ()n .
Z' and G in combination may be W is (a) -CH2-;
(b) -CH=CH-;
(c) -O-;
(d) -NRZ-;
(e) 'S(~)n'~
O
(f) -C- ;
(g) -CRZ(OH)-;
-g_ (h) -CONRZ-;
(i) -NR2C0-;
(j) ; or (k) -C---C-;
R is hydrogen or C,-C6 alkyl;
RZ and R3 are independently (a) hydrogen; or (b) C,-C4 alkyl;
R4 is (a) hydrogen;
(b) halogen;
(c) C,-C6 alkyl;
(d) C,-C4 alkoxy;
(e) C,-C4 acyloxy;
(f) C,-C4 alkylthio;
(g) C,-C4 alkylsulfinyl;
(h) C,-C4 alkylsulfonyl;
(i) hydroxy (C,-C4)aikyl;
lj) aryl (C,-C4)alkyl;
(k) -C02H;
(I) -CN;
(m) -CONHOR;
(n) -S02NHR;
(o) -NH2;
(p) C,-C4 alkylamino;
(q) C,-C4 dialkylamino;
(r) -NHSOZR;
(s) -N02;
(t) -aryl; or (u) -OH;
R5 and R6 are independently C,-C8 alkyl or together form a C3-C,o carbocyclic ring;
R' and R$ are independently (a) phenyl;
(b) a C3-Coo carbocyclic ring, saturated or unsaturated;
(c) a C3-C,o heterocyclic ring containing' up to two heteroatoms, selected from -O-, -N- and -S-;
(d) H;
(e) C,-Cs alkyl; or (f) form a 3 to 8 membered nitrogen containing ring with R5 or Rg R' and R8 in either linear or ring fom~ may optionally be substituted with up to three substituents independently selected from C,-Cs alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R' and R8 may be optionally fused to a phenyl ring;
a is 0, 1 or 2;
m is 1, 2 or 3;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
In another preferred embodiment, the estrogen agonist antagonist is a compound of formula (IA) OCH~CH~G
R°
HG
(IA) wherein G is -N I , or -N
!!I /N
R4 is H, OH, F, or CI; and B and E are independently selected from CH
and N.or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In a preferred embodiment, the estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In another preferred embodiment, the estrogen agonist antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, D-tartrate salt.
In another prefer-ed embodiment, the estrogen agonist antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)'benzyl]-naphthalen-2-ol, (4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW
7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:
(V) O
~(CHy)s ~ t Xp R3B
RIB
RaB
N
RzB
A
(VI) wherein:
R,e is selected from H, OH, -O-C(O~C,-C,2 alkyl (straight chain or branched), -O-C,-C,2 alkyl (straight chain or branched or cyclic), or halogens or C,-Ca halogenated ethers, R28, R3g, R4B, RSB, and RsB are independently selected from H, OH, -O-C(O)-C,-C,2 (straight chain or branched), -O-C,-C,2 (straight chain or branched or cyclic), halogens, or C,-C4 halogenated ethers, cyano, C,-Cg alkyl (straight chain or branched), or trifluoromethyl;
Xp is selected from H, C,-Cg alkyl, cyano, vitro, trifluoromethyl, and halogen;
s is 2 or 3;
Yp is the moiety:
~ /R,B
N
RaB
wherein:
a) R,e and ReB are independently selected from the group of H, C,-Cs alkyl, or phenyl optionally substituted by CN, C,-Cs alkyl (straight chain or branched), C,-Ce alkoxy (straight chain or branched), halogen, -OH, -CF3, or -OCF3; or b) R,B and R8B are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-CQ alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR,e, -NHz, -NH(C~-C4 alkyl), -N(C~-C4 alkyl)2, -NHS02R,B, -NHCOR,B, -NOZ, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or c) R,B and R8B are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR~B, -NH2, -NH(C,-C4 alkyl), -N(C~-C4 alkyl)Z, -NHS02R,g, -NHCOR~B, -N02, or phenyl optionally substituted with 1-3 (C~-C4)alkyl; or d) R,e and R8B are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C~-C4)alkyl, -C02H, -CN, -CONHR,e, -NH2, -NH(C~-CQ alkyl), -N(C~-C4 alkyl)2, -NHS02 R,B, NHCOR,B -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or e) Rye and R8B are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C~-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,e, -NH2, -NH(C,-C4 alkyl), -N(C1-C4 alkyl)2, -NHSOZR,B, -NHCOR,e, -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or f) Rye and RgB are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-Cg alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C~-C4 alkylsulfonyl, hydroxy (C, -C4)alkyl, -C02 H, -CN, -CONHR,B, -NH2, -NH(C~-C4 alkyl), -N(C,-C4 alkyl)2, -NHSOZR,e, -NHCOR~B, -N02, or phenyl optionally substituted with 1-3 (C~-C4) alkyl; or an optical or geometric isomer thereof;
or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound, TSE-424, of formula Va below:
H
(Va) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound EM-652 of formula III below or is EM-800 of formula IV below:
' H
O
C
..
(IV) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
Also provided are drugs for lowering vaginal pH; treating urinary tract infections; treating vaginal dryness; treating vaginal itching; treating undesired vaginal spasms; treating vaginitis; treating vaginal yeast or bacterial infections;
treating vulvar atrophy; treating cystocele, urethocele, rectocele or enterocele prolapse;
treating urinary and anal incontinence; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms, which comprises a therapeutically effective amount of an estrogen agonist~./antagonist.
In a preferred embodiment of the drugs, the patient is a postmenopausal woman.
In another prefer-ed embodiment of the drugs, the estrogen agonist /
antagonist is a compound of formula (I):
' /Y (I) ~B
HO
()e A
wherein:
A is selected from CH2 and NR;
B, D and E are independently selected from CH and N;
Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;
(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;
(c) C3-C8 cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;
Z'-G
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;
(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)S , optionally substituted with 1-3 substituents independently selected from R4;
(f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)S
optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)S , optionally substituted with 1-3 substituents independently selected from R4;
Z' is (a) -(CH2)p W(CH2)q ;
(b) -O(CH2)p CRSRg-;
(c) -O(CHZ)pW(CH2)a-;
(d) -OCHR2CHR3-;
or (e) -SCHR2CHR3-;
G is (a) -NR'R8;
N / (CH2)m~Z2 ~(CH2)n~
(b) wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CHZ-;
optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or Z' and G in combination may be N
-OCH2 ()n W IS
(a) -CHZ-;
(b) -CH=CH-;
(c) -O-;
(d) -NR2-;
(e) -S(O)S ;
O
(f) -C- ;
(g) -CRZ(OH)-;
(h) -CONR2-;
(i) -NRZCO-;
G) ; or (k) -C---C-;
R is hydrogen or C,-C6 alkyl;
R2 and R3 are independently (a) hydrogen; or (b) C,-C4 alkyl;
R4 is (a) hydrogen;
(b) halogen;
(c) C,-C6 alkyl;
(d) C,-C4 alkoxy;
(e) C,-C4 acyloxy;
(f) C,-C4 alkylthio;
(g) C,-C4 alkylsulfinyl;
(h) C,-C4 alkylsulfonyl;
(i) hydroxy (C,-C4)alkyl;
(j) aryl (C,-C4)alkyl;
(k) -COZH;
' 72222-474 (I) -CN;
(m) -CONHOR;
(n) -SOZNHR;
(o) -NH2;
(p) C,-C4 alkylamino;
(q) C~-C4 dialkylamino;
(r) -NHSOZR;
(s) -NO2;
(t) -aryl; or (u) -OH;
RS and Rs are independently C,-C8 alkyl or together form a C3-C,o carbocyclic ring;
R' and R8 are independently (a) phenyl;
(b) a C3-C,o carbocyclic ring, saturated or unsaturated;
(c) a C3-Coo heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-;
(d) H;
(e) C,-Cs alkyl; or (f) form a 3 to 8 membered nitrogen containing ring with R5 or Rs.
R' and R$ in either linear or ring form may optionally be substituted with up to three substituents independently selected from C~-Cs alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R' and R8 may be optionally fused to a phenyl ring;
a is 0, 1 or 2;
m is 1, 2 or 3;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
In another preferred embodiment of the drugs the estrogen agonist /
antagonist is a compound of formula (IA) a . 172222-474 OCH~CH~G
R.
HG
(IA) wherein G is -N I or -N
N
R4 is H, OH, F, or CI; and B and E are independently selected from CH
and N or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In a preferred embodiment of the drugs the estrogen agonist / antagonist is (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of or an optical or geometric isomer thereof; a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt, or a prodrug thereof.
In another preferred embodiment of the drugs the estrogen agonist /
antagonist is the (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8 tetrahydro-naphthalene-2-ol, D-tartrate salt.
In another preferred embodiment of the drugs the estrogen agonist antagonist is selected from tamoxifen, 4-hydroxy tamoxifen, raloxifene, droloxifene, toremifene, centchroman, idoxifene, 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen-2-ol, {4-[2-(2-aza-bicyclo[2.2.1]hept-2-yl)-ethoxy]-phenyl}-(6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone, GW 5638, GW
7604, and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof; or a compound of formulas V or VI:
Xq R38 RIB
\ R4B N) N \
RzB
A
RIB \
RaB
N \
R2e wherein:
A
(VI) RIB is selected from H, OH, -O-C(O)-C,-C~2 alkyl (straight chain or branched), -O-C~-C,2 alkyl (straight chain or branched or cyclic), or halogens or C,-C4 halogenated ethers, RZB, R3B, R4B, R5B, and ReB are independently selected from H, OH, -O-C(O~
C,-C,z (straight chain or branched), -O-C,-C,2 (straight chain or branched or cyclic), halogens, or C,-C4 halogenated ethers, cyano, C~-Cg alkyl (straight chain or branched), or trifluoromethyl;
XA is selected from H, C~-C6 alkyl, cyano, vitro, trifluoromethyl, and halogen;
sis2or3;
YA is the moiety:
\ iR~B
N
RBB
wherein:
a) RIB and R8B are independently selected from the group of H, C,-Ce alkyl, or phenyl optionally substituted by CN, C,-C6 alkyl (straight chain or branched), C,-C6 alkoxy (straight chain or branched), halogen, -OH, -CF3, or -OCF3; or b) RIB and R8g are concatenated to form a five-membered saturated heterocycle containing one nitrogen heteroa#om, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,B, -NHZ, -NH(C,-C4 alkyl), -N(C,-C4 alkyl)2, -NHS02R,B, -NHCOR,B, -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or c) RIB and R8B are concatenated to form a six-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,e, -NH2, -NH(C,-C4 alkyl), -N(C,-C4 alkyl)2, -NHS02R,B, -NHCOR,B, -N02, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or d) RIB and R88 are concatenated to form a seven-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-CQ alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,B, -NH2, -NH(C,-C4 alkyl), -N(C,-C4 alkyl)2, -NHS02 R,B, -NHCOR,e -NO2, or phenyl optionally substituted with 1-3 (C,-CQ)alkyl; or e) RIB and R8B are concatenated to form an eight-membered saturated heterocycle containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-CQ alkoxy, trihalomethoxy, C,-acyloxy, C,-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR~B, -NH2, -NH(Ci-C4 alkyl), -N(C1-C4 alkyl)2, -NHSOZR,B, -NHCOR,e, -NOZ, or phenyl optionally substituted with 1-3 (C,-C4)alkyl; or f) R,B and R$B are concatenated to form a saturated bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing one nitrogen heteroatom, the heterocycle being optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C~-C4 alkoxy, trihalomethoxy, C,-C4 acyloxy, C~-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C, -C4)alkyl, -COZ H, -CN, -CONHR,B, -NH2, -NH(C~-C4 alkyl), -N(C~-CQ alkyl)2, -NHS02R,g, -NHCOR~B, -NO2, or phenyl optionally substituted with 1-3 (C~-C4) alkyl; or an optical or geometric isomer thereof;
or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound, TSE-424, of formula Va below:
H
(Va) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof; or the compound EM-652 of formula III below or is EM-800 of formula IV below:
(III) O
C
N
O ~ ,., ~CH3 (IV) or an optical or geometric isomer thereof; or a pharmaceutically acceptable salt, N-oxide, ester, quaternary ammonium salt or prodrug thereof.
Also provided by the present invention are kits for use by a consumer to improve or maintain urogenital health comprising:
~
, (a) a pharmaceutical composition comprising an estrogen agonist/antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and (b) a written matter describing indications or instructions for use of the pharmaceutical composition to improve or maintain urogenital health; lower vaginal pH;
treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis; treat vaginal yeast or bacterial infections;
treat vulvar atrophy; treat cystocele, urethrocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency;
or increase the frequency or intensity, of orgasms.
In another embodiment of the kits, an additional compound useful to improve or maintain urogenital health;
lower vaginal pH; treat urinary tract infections; treat vaginal dryness; treat vaginal itching; treat undesired vaginal spasms; treat vaginitis~ treat vaginal yeast or bacterial infections; treat vulvar atrophy; treat cystocele, urethrocele, rectocele or enterocele prolapse; treat urinary or anal incontinence; treat undesired urinary frequency or urgency; or increase the frequency or intensity of orgasms is included in the kit.
The present invention also provides a use of an estrogen agonist/antagonist for lowering vaginal pH;
treating vaginitis; treating a vaginal yeast or bacterial infection; treating vulvar atrophy; treating urethrocele, cystocele, rectocele, or enterocele prolapse; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms in a female patient.
The present invention also provides a use of an estrogen agonist/antagonist for the manufacture of a -25a-medicament for lowering vaginal pH; treating vaginitis:
treating a vaginal yeast or bacterial infection; treating vulvar atrophy; treating urethrocele, cystocele, rectocele, or enterocele prolapse; treating undesired urinary frequency or urgency; or increasing the frequency or intensity of orgasms in a female patient.
Also provided are methods for assessing vaginal health in a patient, the methods comprising:
a) conducting a gynecological examination;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index;
d) determining vaginal prolapse;
e) administering a questionnaire to the patient; and f) measuring plasma hormone levels, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
In a preferred embodiment of the methods, the gynecological examination comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length.
In another preferred embodiment of the methods, the gynecological exam further comprises an assessment of the quantity of pubic hair and the thickness of the vulva:
In another preferred embodiment of the methods, the plasma hormone levels that are measured include estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione.
In another preferred embodiment of the methods, vaginal prolapse is determined by grading the prolapse using the following scale:
Grade normal position inside the mid-vaginal axis for 0 anterior posterior wall prolapse and above the ischial spines for cervical or vaginal cuff. By definition, the most apical point is -3 cm superior to the hymen.
Grade if the prolapse crosses the respective thresholds 1 and descends halfway to the hymen Grade descent,to the hymen Grade descent 2 cm beyond the hymen Grade maximum possible descent for each site. A complete 4 eversion is about 5 cm beyond hymen.
In another preferred embodiment of the methods, the questionnaire comprises questions relating to:
1 ) the number of vaginal infections;
2) the number of urinary infections;
7 5 3) the amount of urinary leakage;
4) the degree of vaginal dryness;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient.
Also provided are methods for assessing vaginal health in a patient, the methods comprising:
a) conducting a gynecological examination that comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length; and assessing the quantity of pubic hair and the thickness of the vulva;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index ;
d) determining vaginal prolapse using the following scale:
Grade normal position inside the mid-vaginal axis for 0 anterior posterior wall prolapse and above the ischial spines for cervical or vaginal cuff. By definition, the most apical point is -3 cm superior to the hymen.
Grade if the prolapse crosses the respective thresholds 1 and descends halfway to the hymen Grade descent to the hymen Grade descent 2 cm beyond the hymen Grade maximum possible descent for each site. A complete 4 eversion is about 5 cm beyond hymen.
e) administering a questionnaire to the patient, the questionnaire comprising questions relating to:
1 ) the number of vaginal infections in a specified time period;
2) the number of urinary infections in a specified time period;
3) the amount of urinary leakage in a specified time period;
4) the degree of vaginal dryness in a specified time period;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient;
and f) measuring plasma levels of estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
n i DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to drugs and kits for improving or maintaining urogenital health. Specifically, the invention relates to drugs of lowering vaginal pH, treating urinary tract infections, treating vaginal dryness, treating vaginal itching, treating undesired vaginal spasms, treating vaginitis, treating vaginal yeast or bacterial infections, treating vulvar atrophy, treating urethrocele, cystocele, rectocele, or enterocele prolapse, treating urinary or anal incontinence, treating undesired urinary frequency or urgency, and increasing the frequency and intensity of orgasms. The present invention also relates to methods for assessing vaginal health, which are useful for determining the efficacy and safety of new pharmaceutical substances and compositions that affect the vagina and for making diagnostic decisions.
As used herein, the terms "treat", "treatment" and "treating" include preventative (e.g., prophylactic) and palliative treatment of the disease or condition, or amelioration of a symptom of the disease or condition.
The phrase Nmaintaining or improving urogenital health" means the prevention of pathological urogenital conditions or symptoms of the conditions or a slowing of the processes underlying the conditions or the development of the symptoms of the conditions or a reversal of the conditions or a reversal of the symptoms of the conditions. An improvement in urogenital health may include a reduction in the urogenital infections, including vaginal and urinary infections; a reduction in vaginal dryness, itching and irritation; and/or a reduction of incontinence. An improvement in urogenital health may also include the maintenance or improvement of pelvic floor integrity, which includes prolapse.
The term "incontinence" includes urinary and anal incontinence. When the incontinence is urinary in nature, it is defined as involuntary urine loss that is a social or hygienic problem. Urinary incontinence may be stress incontinence, urge incontinence or mixed incontinence which is stress and urge incontinence occurring together, or it may be unconscious incontinence which occurs without urgency and without conscious recognition of leakage. There may be hesitancy, straining to void, poor stream as indicated by a decreased force of flow of the urinary stream.
Intermittent stream may be noted as a "stop and start" pattern of urination.
Or there may be incomplete emptying of the bladder or postmicurition dribble that is urine loss occurring just after normal urination has been completed.
"Anal incontinence" is the involuntary loss of feces or flatus that may be caused by rectal prolapse. Normally, the rectum is attached firmly to the levator ani muscle complex through an extensive interweaving of longitudinal muscle fibers.
These attachments are important because the rectum undergoes multiple changes in position and location during the act of normal defecation. Without this attachment, the rectum would slip down through the levator muscle hiatus during defecation. In rectal prolapse, this occurs.
A "prolapse" is a downward or forward displacement of one of the pelvic organs from its normal location. Traditionally, prolapse has referred to displacement of the bladder, the uterus, or rectum. Prolapse can also relate to displacement of the vagina. These displacements have usually been graded on a scale of 0-4; the grade increases with increasing severity of the prolapse. A
variety of terms are used to describe female genital prolapse that have been fixed in the literature, which terms include:
A "cystocele" is a downward displacement of the bladder.
A "cystourethocele" is a cystocele that includes the urethra as part of the prolapsing organ complex.
A "uterine prolapse" is descent of the uterus and cervix down the vaginal canal toward the vaginal introitus.
A "rectocele" is a protrusion of the rectum into the posterior vaginal lumen.
A "enterocele° is a herniation of the small bowel into the vaginal lumen.
The term "vaginitis" means inflammation of the vagina.
The phrase "undesired urinary frequency or urgency" means that a patient urinates more often than an average of a group of similar patients. Typically, this increased number of urinations makes the patient psychologically uncomfortable and is embarrassing. In addition, a patient can experience an enhanced sense of the need to urinate when compared with a similar group. This heightened sense of needing to urinate can also lead to psychological discomfort and embarrassment.
The term "increasing the frequency or intensity of orgasms" means that a patient experiences more orgasms or experiences or perceives a heightened intensity of orgasms after treatment with the present compounds than without treatment. A way to measure a patient's perception of increased number of orgasms and/or increased intensity of orgasms is to ask the patient. For example, a questionnaire can be used.
Some aspects of vaginal health status can be determined by analysis of vaginal secretions. Normal vaginal secretions are floccular in consistency, white in color, and usually located in the dependent portion of the vagina (posterior fomix).
Vaginal secretions can be analyzed by a wet-mount preparation. A sample of vaginal secretions is suspended in 0.4 mL of normal saline in a glass tube, transferred to a slide, covered with a slip, and assessed by microscopy. Some clinicians prefer to prepare slides by suspending secretions in saline placed directly on the slide.
Secretions should not be placed directly on the slide without saline because this method causes drying of the vaginal secretions and does not result in a well-suspended preparation. Microscopy of normal vaginal secretions reveals many superficial epithelial cells, a few white blood cells (less than one per epithelial cell), and few, if any, clue cells. Clue cells are superficial vaginal epithelial cells with adherent bacteria, usually G. vaginalis, which obliterates the crisp cell border and usually can be visualized microscopically. Potassium hydroxide 10% (KOH) may be added to the slide, or a separate preparation can be made, to examine the secretions for fungal elements. The results should be negative for women with normal vaginal microbiology. Gram stain will reveal that normal superficial epithelial cells appear normal and a predominance of gram positive rods (lactobacilli).
The phrase "adverse effects associated with estrogen" include breast tenderness, bloating, headache, increased blood clotting and menstrual bleeding in women and breast cancer. Estrogen therapy increases the risk of endometrial carcinoma. Women on long-term estrogen therapy may have an increased risk that is got reversed by concurrent administration of progestin (N Engl J Med 195;332:1589).
The term "postmenopausal women" is defrned to include not only women of advanced age who have passed through menopause, but also women who have been hysterectomized or for some other reason have suppressed estrogen production, such as those who have undergone long-term administration of corticosteroids, suffer from Cushings' syndrome, have gonadaf dysgenesis or who have undergone radiation therapy.
"Breast cancer" is defined as a malignant proliferation of epithelial cells lining the ducts or lobules of the breast.
The term "patient" means animals, particularly mammals. Preferred patients are humans, with postmenopausal female humans being the most preferred patients.
An "estrogen agonist / antagonist" is a compound that affects some of the same receptors that estrogen does, but may not affect all, and in some instances, it antagonizes or blocks estrogen. It is also known as a "selective estrogen receptor modulator" (SERM). Estrogen agonists / antagonists may also be referred to as antiestrogens although they have some estrogenic activity at some target tissues.
Estrogen agonists / antagonists are therefore not what are commonly referred to as "pure antiestrogens". Antiestrogens that can also act as agonists are referred to as Type I antiestrogens. Type I antiestrogens activate the estrogen receptor to bind tightly in the nucleus for a prolonged time but with impaired receptor replenishment (Clark, et al., Steroids, 1973;22:707, Capony et al., Mol Cell Endocrinol, 1975;3:233).
When a woman reaches menopause, changes in the urogenital system can occur. These changes include increased vaginal pH; increased number of vaginal yeast and bacterial infections, which can be exacerbated by increased vaginal pH;
increased vaginal dryness and itching; undesired vaginal spasms; vaginitis;
vulvar atrophy; various types of prolapse as described herein; and urinary or anal incontinence, which can be the result of a prolaspse. In accordance with the present invention, these conditions can be treated by administering an estrogen agonist / antagonist. By treating these conditions, the overall vaginal health of a patient is maintained or improved.
The estrogen agonists / antagonists of the invention may be administered systemically or locally. For systemic use, the estrogen agonists / antagonists herein are formulated for parenteral (e.g., intravenous, subcutaneous, intramuscular, intraperitoneal, intranasal or transdermal) or enteral (e.g., oral or rectal) delivery according to conventional methods. Intravenous administration can be by a series of injections or by continuous infusion over an extended period.
Administration by injection or other routes of discretely spaced administration can be performed at intervals ranging from monthly, weekly to once to three or more times daily.
Another method of administering compounds of the present invention includes the use of topical dosage forms. For example, the active agent can be administered to a patient in a cream or ointment that is applied to the skin, particularly the skin of the vagina. Alternatively, the active agent can be delivered using a patch that is applied to the skin. The use of a topical dosage form is particularly useful in treating vaginal dryness, urinary and/or vaginal bacterial or yeast infections and dyspureunia.
Preferred estrogen agonists / antagonists that can be used in the methods and kits of the present invention include the compounds described in U.S.
patent number 5,552,412. Those compounds are described by the formula designated herein as formula (I) given below:
~Y U) HO-a wherein:
A is selected from CH2 and NR;
B, D and E are independently selected from CH and N;
Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;
(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;
(c) C3-Ca cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;
(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)~-, optionally substituted with 1-3 substituents independently selected from R4;
2'-G
t (f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n- optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)S , optionally substituted with 1-3 substituents independently selected from R4;
Z' is (a) -(CH2)P W(CHZ)q-;
(b) -O(CH2)P CR5R6-;
(c) -O(CH2)PW(CH2)q-;
(d) -OCHR2CHR3-; or (e) -SCHR2CHR3-;
G is (a) -NR'R8;
(b) N ~ (CH2)m'~Z2 ~(CH2)n-"~
wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CH2-;
optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or Z' and G in combination may be N
-OCHz ()n , W IS
(a) -CHz-;
(b) -CH=CH-;
_O-;
(d) -NRZ-;
(e) -S(O)n-, O
(f) -C
(g) -CRZ(OH)-;
(h) -CONRZ-;
(i) -NR2C0-;
G) ; or (k) -C--__C-;
R is hydrogen or C~-C6 alkyl;
R2 and R3 are independently (a) hydrogen; or (b) C,-C4 alkyl;
R4 is (a) hydrogen;
(b) halogen;
(c) C~-C6 alkyl;
(d) C,-C4 alkoxy;
(e) C,-C4 acyloxy;
(f) C,-C4 alkylthio;
(g) C,-C4 alkylsulfinyl;
(h) C~-C4 alkylsulfonyl;
(i) hydroxy (C~-C4)alkyl;
(j) aryl (C,-C4)alkyl;
(k) -C02H;
(I) -CN;
(m) -CONHOR;
(n) -SOZNHR;
(o) -NHZ;
(p) C,-C4 alkylamino;
(q) C,-C4 dialkylamino;
(r) -NHS02R;
(s) -N02;
(t) -aryl; or (u) -OH;
R5 and R6 are independently C,-C8 alkyl or together form a C3-C,o carbocyclic ring;
R' and R$ are independently (a) phenyl;
(b) a C3-C,o carbocyclic ring, saturated or unsaturated;
(c) a C3-C,o heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-;
(d) H;
(e) C,-C6 alkyl; or (f) form a 3 to 8 membered nitrogen containing ring with R5 or R6;
R' and Ra in either linear or ring form may optionally be substituted with up to three substituents independently selected from C,-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R' and R$ may be optionally fused to a phenyl ring;
a is 0, 1 or 2;
m is 1, 2 or 3;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
and optical and geometric isomers thereof; and nontoxic pharmacologically acceptable acid addition salts, N-oxides, esters, quaternary ammonium salts and prodrugs thereof.
Additional preferred compounds of the invention also disclosed in U.S.
patent number 5,552,412 are described by the formula designated herein as formula (IA):
OCH~CH~G
HG
(IA) -N~ ~ or -N
wherein G is ' /N
R' is H, OH, F, or CI; and B and E are independently selected from CH
and N, and pharmaceutically acceptable salts thereof.
Especially preferred compounds for the methods of the invention are:
cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd ro-naphthalene-2-ol;
cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7, 8-tetrahyd ro-naphthalene-2-ol;
cis-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene;
1-(4'-pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;
cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
1-(4'-pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and pharmaceutically acceptable salts thereof. An especially preferred salt of (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of is the D-tartrate salt.
The syntheses of compounds of formula (I) are set forth in U.S. patent number 5,552,412.
Other preferred estrogen agonists / antagonists are disclosed in U.S. patent number 5,047,431. The structure of these compounds are described by the formula designated herein as formula (II) below:
OCH~CH~N, OH
wherein R'A and R~'' may be the same or different and are either H, methyl, ethyl or a benzyl group; and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof. A particularly preferred compound is droloxifene. The syntheses of the compounds of formula (II) are set forth in U.S. patent number 5,047,431 Additional preferred estrogen agonists / antagonists are tamoxifen:
(ethanamine,2-[-4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl, (Z)-2-, 2-hydroxy-1,2,3-propanetricarboxylate(1:1)) and other compounds as disclosed in U.S.
patent number 4,536,516; 4-hydroxy tamoxifen (i.e., tamoxifen wherein the 2-phenyl moiety has a hydroxy group at the 4 position) and other compounds as disclosed in U.S.
patent number 4,623,660; raloxifene: (methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride) and other compounds as disclosed in U.S. patent numbers 4,418,068; 5,393,763;
5,457,117; 5,478,847 and 5,641,790; toremifene: (ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and other compounds as disclosed in U.S. patent numbers 4,696,949 and 4,996,225; centchroman: 1-[2-[[4-(-methoxy-2,2, dimethyl-phenyl-chroman-4-yl)-phenoxy]-ethyl]-pyrrolidine and other compounds as disclosed in U.S. Patent 3,822,287; idoxifene: pyrrolidine, 1-[-[4-[[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl] and other compounds as disclosed in U.S. patent number 4,839,155; 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen -2-0l and other compounds as disclosed in U.S. patent number 5,484,795; and {4-[2-(2-aza-bicyclo[2.2.1 ]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone and other compounds as disclosed in published international patent application WO 95/10513.
Further preferred estrogen agonists / antagonists include EM-652 (as shown in the formula designated herein as formula (ill) and EM-800 (as shown in the formula designated herein as formula (IV)). The synthesis of EM-652 and EM-800 and the activity of various enantiomers is described in Gauthier et al., J.
Med. Chem., 1997;40:2117-2122.
(III) N
O
H C \CH3 (IV) Further preferred estrogen agonists / antagonists include TSE 424 and other compounds disclosed in U.S. patent number 5,998,402, U.S. patent number 5,985,910, U.S. patent number 5,780,497, U.S. patent number 5,880,137, and European patent application EP 0802183 A1 including the compounds described by the formulae designated herein as formulae V and VI, below:
XA Rse RIB
(v) Rze R.
A
O
C
xA R3B
R,B \
RaB
/, N \
RzB
Hz)s YA
wherein:
R,B is selected from H, OH or the C,-C~2 esters (straight chain or branched) or C,-C~2 (straight chain or branched or cyclic) alkyl ethers thereof, or halogens; or C,-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether;
RZB, R3g, RaB, R5B, and ReB are independently selected from H, OH or the C,-C~2 esters (straight chain or branched) or C,-C~2 alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C,-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, C~-Cg alkyl (straight chain or branched), or trifluoromethyl;
XA is selected from H, C~-C6 alkyl, cyano, vitro, trifluoromethyl, and halogen;
s is 2 or 3;
YA is selected from:
a) the moiety:
\ iR~B
Rae wherein R,B and R8B are independently selected from the group of H, C~-Cs alkyl, or phenyl optionally substituted by CN, C~-Cs alkyl (straight chain or branched), C~-Cs alkoxy (straight chain or branched), halogen, -OH, -CF3, or -OCF3;
b) a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C~-Ca alkyl)-, -N=, and -S(O)S , wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C~-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H-, -CN, -CONHR,B, -NH2, C,-C4 alkylamino, di(C,-C4)alkylamino, -NHS02R,B, -NHCOR~B; -N02, and phenyl optionally substituted with 1-3 (C,-C4)alkyl;
c) a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C,-C4 alkyl)-, -N=, and -S(O)S , wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C~-C4 alkoxy, trihalomethoxy, C~-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C~-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR~B-, -NH2, C,-Cq alkylamino, di(C,-C4)alkylamino, -NHS02R,B, -NHCOR,B, -NOZ, and phenyl optionally substituted with 1-3 (C,-C4)alkyl;
d) a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C~-C4 alkyl)-, -N=, and -S(O)~-, wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C~-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C~-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR~B, -NH2, C,-C4 alkylamino, di(C~-C4)alkylamino, -NHSOZR~$, -NHCOR~B, -NOZ, and phenyl optionally substituted with 1-3 (C,-C4)alkyl; or e) a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C~-C4 alkyl)-, and -S(O)S , wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,B, -NH2, -N=, C,-C4 alkylamino, di(C~-C4)alkylamino, -NHS02R,B, -NHCOR,e, -N02, and phenyl optionally substituted with 1-3 (C,-C4) alkyl; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.
The more preferred compounds of this invention are those having the general structures V or VI, above, wherein:
R,B is selected from H, OH or the C,-C,2 esters or alkyl ethers thereof, and halogen;
RZB, R3B, R4B, R5B, and RgB are independently selected from H, OH or the C~-C~2 esters or alkyl ethers thereof, halogen, cyano, C,-Cs alkyl, or trihalomethyl, preferably trifluoromethyl;
XA is selected from H, C,-CB alkyl, cyano, vitro, trifluoromethyl, or halogen;
YA is the moiety:
\ iR~e N
RIB and R$B are selected independently from H, C,-Cg alkyl, or combined by -(~H2)w , wherein w is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C~-C4 alkyl, trihalomethyt, C~-C4 alkoxy, trihalomethoxy, C~-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONH(C,-C4), -NH2, C,-C4 alkylamino, C~-C4 dialkylamino, -NHS02(C~-C4), -NHCO(C,-C4), and -N02; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.
The rings formed by a concatenated Rye and RaB, mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
The most preferred compounds of structural formulas V and VI, above, are those wherein RIB is OH; R28 - RsB are as defined above; XA is selected from the group of CI, N02, CN, CF3, or CH3; YA is the moiety N
Ree and R,B and R8B are concatenated together as -(CH2)t-, wherein t is an integer of from 4 to 6, to form a ring optionally substituted by up to three subsituents selected from the group of hydrogen, hydroxyl, halo, C~-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONH(C,-C4)alkyl, -NHz, C,-C4 alkylamino, di(C~-C4)alkylamino, -NHS02(C,-C4)alkyl, -NHCO(C,-C4)alkyl, and -N02; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.
In a preferred embodiment, the compound is TSE-424 as described by the formula designated herein as formula (Va) below:
OH
H
(Va) The syntheses of compounds of formulas V, Va and VI are set forth in U.S.
patent number 5,998,402. The pharmaceutically acceptable salts of the estrogen agonists / antagonists of this invention may be formed of the compound itself, or of any of its esters, and include the pharmaceutically acceptable salts which are often used in pharmaceutical chemistry. For example, salts may be formed with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfonic acids including such agents as naphthalenesulfonic, methanesulfonic and toluenesulfonic acids, sulfuric acid, nitric acid, phosphoric acid, tartaric acid, pyrosulfuric acid, metaphosphoric acid, succinic acid, formic acid, phthalic acid, lactic acid and the like, most preferable with hydrochloric acid, citric acid, benzoic acid, malefic acid, acetic acid or propionic acid.
The estrogen agonists / antagonists of this invention, as discussed above, can be administered in the form of pharmaceutically acceptable salts. The salts are conveniently formed, as is usual in organic chemistry, by reacting the compound of this invention with a suitable acid, such as has been described above. The salts are quickly formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash as the final step of the synthesis. The salt-forming acid is dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if the compound of this invention is desired in the free base form, it is isolated from a basic final wash step, according to the usual practice. A preferred technique for preparing hydrochlorides is to dissolve the free base in a suitable solvent and dry the solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it. A prefer-ed salt of (-)-cis-6-phenyl-5-[4-(2-pyn-olidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of is the D-(-)-tartrate salt. It will also be recognized that it is possible to administer amorphous forms of the estrogen agonists / antagonists.
The expression "pharmaceutically acceptable salts" includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. The expression "pharmaceutically-acceptable cationic salts" is intended to define but is not limited to such salts as the alkali metal salts, (e.g.
sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), aluminum salts, ammonium salts, and salts with organic amines such as benzathine (N,N'-dibenzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine. The expression "pharmaceutically-acceptable acid addition salts" is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
One of ordinary skill in the art will recognize that certain estrogen agonists /
antagonists of this invention will contain one or more atoms which may be in a particular stereochemical, tautomeric, or geometric configuration, giving rise to stereoisomers, tautomers and configurational isomers. All such tautomers and isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are also included.
The subject invention also includes isotopicaily-labeled estrogen agonists /
antagonists, which are structurally identical to those disclosed above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2H, 3H, '3C, '4C, 'SN, '80, "O, 3'P, ~F, 355, '8F and SCI, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and'4C
are incorporated, are useful in compound and/or substrate tissue distribution assays.
Tr-itiated, i.e., 3H, and carbon-14, i.e., '4C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
Certain ester groups are preferred when a compound of this invention contains an ester. The estrogen agonists / antagonists including the compounds of formula I, IA, li, III, IV, V, Va, or VI may contain ester groups at various positions as .y defined herein above, where these groups are represented as -COORS, R9 is C,-C,4 alkyl, C,-Cs chloroalkyl, C,-C3 fluoroalkyl, C5-C~ cycloalkyl, phenyl, or phenyl mono-or disubstituted with C,-C4 alkyl, C,-C4 alkoxy, hydroxy, nitro, chloro, fluoro or tri(chloro or fluoro)methyl.
As used herein, the term "effective amount" means an amount of an estrogen agonist / antagonist or combination of estrogen agonists / antagonists that is capable of treating the described pathological condition. The specific dose of a compound or combination of compounds administered according to this invention will, of course, be determined by the particular circumstances including, for example, the compound or combination administered, the route of administration, and the severity of the pathological condition being treated.
The dose of a compound of this invention to be administered to a patient is rather widely variable and subject to the judgement of the attending physician. It should be noted that it may be necessary to adjust the dose of a compound when it is administered in the form of a salt, such as a laureate, the salt forming moiety of which has an appreciable molecular weight.
The following dosage amounts and other dosage amounts set forth elsewhere in this description and in the appendant claims are for an average human patient having a weight of about 65 kg to about 70 kg. The skilled practitioner will readily be able to determine the dosage amount required for a patient whose weight falls outside the 65 kg to 70 kg range. All doses set forth herein, and in the appendant claims, are daily doses of the free base form of the estrogen agonists /
antagonists.
Calculation of the dosage amount for other forms of the free base form such as salts or hydrates is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
The general range of effective administration rates of the estrogen agonists /
antagonists is from about 0.001 mg/daylkg body weight to about 200 mg/day/kg body weight. A preferred rate range is from about 0.010 mg/day/kg body weight to 100 mg/day/kg body weight. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day.
However, in any given case, the amount of compound administered will depend on such factors as the potency of the specific estrogen agonist / antagonist, the solubility of the compound, the formulation used and the route of administration.
For (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, L-tartrate salt, a preferred dosage range for humans is about 0.025 mglday/kg body weight to about 1 mg/day/kg body weight. A more preferred dosage range is about 0.25 mg/day/kg body weight to about 0.5 mg/day/kg body weight.
Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995). Pharmaceutical compositions for use within the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.
Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline celiulose,.sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.
Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
A lubricant may be necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.
Tablet disintegrators are substances that facilitate the disintegration of a tablet to release a compound when the tablet becomes wet. They include starches, ~ clays, celluloses, algins and gums, more particularly, com and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used as well as sodium lauryl sulfate.
Tablets are often coated with sugar as a flavorant and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet.
The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established in the art.
When it is desired to administer a compound as a suppository, the typical bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use.
The effect of the compounds may be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Topical formulations may be designed to yield delayed and/or prolonged percutaneous absorption of a compound. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.
The term "prodrug" means a compound that is transformed in vivo to yield a cor~npound of the present invention. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A good discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, °Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
For example, if a compound of the present invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C,-C$)alkyl, (C2-C~2)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C~-C2)alkylamino(Cz-C3)alkyl (such as (3-dimethylaminoethyl), carbamoyl-(C,-C2)alkyl, N,N-di(C~-CZ)alkylcarbamoyl-(C~-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl.
Similarly, if a compound of the present invention comprises an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C,-Cg)alkanoyloxymethyl, 1-((C~-C6)alkanoyloxy)ethyl, 1-methyl-1-((C,-Cg)alkanoyloxy)ethyl, (C~-Cs)alkoxycarbonyloxymethyl, N-(C~-Cs)alkoxycarbonylaminomethyl, succinoyl, (C,-C6)alkanoyl, a-amino(C,-C4)alkanoyl, arylacyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl, where each a-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C~-Cs)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
If a compound of the present invention comprises an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R"-carbonyl, R"O-carbonyl, NRXRX'-carbonyl where Rx and RX' are each independently (C~-C~°)alkyl, (C3-C~)cycloalkyl, benzyl, or R"-carbonyl is a natural a-aminoacyl or natural a-aminoacyl-natural a-aminoacyl, -C(OH)C(O)OY" wherein Y" is H, (C,-Ce)alkyl or benzyl, -C(OY"°) Y"' wherein YXo is (C,-C4) alkyl and YX' is (C,-Ce)alkyl, carboxy(C~-C6)alkyl, amino(C~-C4)alkyl or mono-N- or di-N,N-(C~-Cs)alkylaminoalkyl, -C(Y"2) Y"3 wherein Y"2 is H or methyl and Y"3 is mono-N- or di-N,N-(C,-C6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yi.
Advantageously, the present invention also provides kits for use by a cansumer to improve or maintain urogenital health. The kits comprise a) a pharmaceutical composition comprising an estrogen agonist / antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and b) instructions describing a method of using the pharmaceutical compositions to improve or maintain urogenital health. The instructions may also indicate that the kit is to improve or maintain urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
A "kit" as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form.
For example, tablets may be contained in a bottle that is in turn contained within a box.
An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
It may be desirable to provide a written memory aid, where the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or patient, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested or a card which contains the same type of information. Another example of such a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday," . . . etc . . . .
"Second Week, Monday, Tuesday, . . ." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several tablets or capsules to be taken on a given day.
Another specifrc embodiment of a kit is a dispenser designed to dispense the daily doses one at a time. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
It is noted that an estrogen agonist / antagonist can be used in combination with other different estrogen agonists / antagonists to maintain or improve urogenital health. In addition, estrogen agonists /antagonists can be used in combination with estrogen. Estrogen agonists / antagonists can also be used in combination with one or more additional compounds that are therapeutically useful to improve or maintain urogenital health. For example, estrogen agonists / antagonists can be used in combination with compounds that are used to treat urinary incontinence, anal incontinence, vaginal infections, urinary infections, vaginal dryness, vaginal itching, or pelvic floor integrity, including vaginal prolapse. Examples of additional compounds that can be used in combination with an estrogen agonist / antagonist include Detrol~
and anti-fungal and anti-bacterial products.
In addition, an estrogen agonist / antagonist can be used in combination with agents that can be used to acidify (i.e., lower pH) the urinary tract and/or vagina.
Examples of such agents include potassium acid phoshate and sodium acid phosphate.
An estrogen agonist / antagonist can be used in combination with a cGMP
elevator agent to treat the conditions disclosed herein.
Prefer-ed as the cGMP elevator are cGMP phosphdiesterase (PDE) inhibitors. cGMP PDE inhibitors that are selective for cGMP PDEs rather than cyclic adenosine 3',5'-monophosphate phosphodiesterases (CAMP PDEs) and that are selective inhibitors of the cGMP PDE" isoenzyme are particularly preferred.
Such particularly preferred cGMP PDE inhibitors are disclosed in US patents 5,250,534;
5,346,901; 5,272,147; and in the international patent application WO 94/28902.
Preferred cGMP PDE~ inhibitors include compounds of formula (VII):
R3c0 HN
(vll) Rac wherein:
R'c is H; C~-C3 alkyl; C~-C3 perfluoroalkyl; or C3-C5 cycloalkyl;
Rzc is H; C,-Cs alkyl optionally substituted with C3-Cs cycloalkyl; C,-C3 perfluoroalkyl; or C3-Cs cycloalkyl;
R3c is C,-Cs alkyl optionally substituted with C3-Cs cycloalkyl; C,-Cs perfluoroalkyl; C3-CS cycloalkyl; C3-Cs alkenyl; or C3-Cs alkynyl;
R4c is C~-C4 alkyl optionally substituted with OH, NRSCRsc, CN, CONR5cRsc or C02R'c; C~-C4 alkenyl optionally substituted with CN, CONRSCRsc or COZR'c; C~-alkanoyl optionally substituted with NRSCRsc; (hydroxy)C2-C4 alkyl optionally substituted with NRSCRsc; (C2-C3 alkoxy)C~-C2 alkyl optionally substituted with OH or NRSCRsc; CONRSCRsc; C02R'c; halo; NRSCRsc; NHS02NR5cRsc; NHS02R8c;
SOZNR9cR'°c or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl;
R5c and Rsc are each independently H or C,-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R"c)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH;
R'c is H or C,-C4 alkyl;
Rsc is C,-C3 alkyl optionally substituted with NRSCRsc;
R9c and R'°c together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N(R'ZC)-piperazinyl group wherein said group is optionally substituted with C~-C4 alkyl, C,-C3 alkoxy, NR'3cR'4c or CONR'3cR'4c;
R"C is H; C,-C3 alkyl optionally substituted with phenyl; (hydroxy)C~-C3 alkyl; or C,-C4 alkanoyl;
R'x is H; C,-Cs alkyl; (C1-C3 alkoxy)C~-Cs alkyl; (hydroxy)CrCs alkyl;
(RtscR,acN)C2-Ce alkyl; (R'~R'4cNOC)C,-Cs alkyl; CONR'3cR'"c; CSNR'3cR'4c; or C(NH)NR'3cR'''c; and R'3~ and R'4~ are each independently H; C~-C4 alkyl; (C~-C3 alkoxy)C2-C4 alkyl;
or (hydroxy)C2-C4 alkyl; and pharmaceutically acceptable salts thereof.
Prefers-ed cGMP PDEv inhibitors include 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine (sildenafil) which has the structure of formula (VIII):
N
CH3CHz0 H
O ~ H3 (VIII) and pharmaceutically acceptable salts thereof; the compound having the structure of formula (IX):
i i . . .....
O ~ H3 N~
\N
J ~H2~
c~
(IX) and pharmaceutically acceptable salts thereof; and the compound 3-ethyl-5-{5-[(4-ethylpiperazino) sulphonyl]-2-(2-methoxyethoxy)pyrid-3-yl}-2-(2-pyridylmethyl)-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-7-one of formula (X):
O
ni / v O=S=
N
N
J
(X) The compound of formula (IX) is disclosed, for example, in US Patents 5,272,147 and 5,426,107.
A preferred pharmaceutically acceptable salt of sildenafil for use in this invention is the citrate salt, and a preferred dosage range is from about 1 mg to about 100 mg.
Also preferred as cGMP PDE~ inhibitors are compounds disclosed in WO
95/19978 having the formula (XI):
~N_R~°
N Ra°
N
~° O
(XI) and salts and solvates thereof, in which:
R°° represents hydrogen, halogen or C,-Csalkyl,;
R'° represents hydrogen, C~-Csalkyl, C2-Csalkenyl, Cz-Csalkynyl, haloC,-Csalkyl, C3-CBcycloalkyl, C3-C$cycloaIkyIC,-C3alkyl, arylC~-C3alkyl or heteroarylC~-C3alkyl;
R2° represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally A
substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atams and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3° represents hydrogen or C,-C3alkyl, or R'° and R3° together represent a 3- or 4-membered alkyl or alkenyl ring.
A preferred group of compounds having formula Xla (also disclosed in WO
95!19978) includes compounds of the formula:
~N_R1D
N
N
~° O
(Xla) and salts and solvates thereof, in which:
R°° represents hydrogen, halogen or C~-Csalkyl;
R'° represents hydrogen, C,-CBalkyl, haloC,-Cealkyl, C3-Cscycloalkyl, C3-CBcycloalkyl-C~-C3alkyl, arylC~-C3alkyl or heteroarylC,-C3alkyl; and R2° represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally A
substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen.
cGMP elevators of the present invention include produgs, geometric isomers, stereoisomers, hydrates, tautomers and salts of the described compounds.
Suitable cGMP PDE inhibitors also include those disclosed in the following US patents:
a 5-substituted pyrazolo[4,3-d]pyrimidine-7-one disclosed in US 4,666,908;
a griseolic acid derivative disclosed in any of US 4,634,706, 4,783,532, 5,498,819, 5,532,369, 5,556,975, and 5,616,600;
a 2-phenylpurinone derivative disclosed in US 4,885,301;
a phenylpyridone derivative disclosed in US 5,254,571;
a fused pyrimidine derivative disclosed in US 5,047,404;
a condensed pyrimidine derivative disclosed in US 5,075,310;
a pyrimidopyrimidine derivative disclosed in US 5,162,316;
a purine compound disclosed in US 5,073,559;
a quinazoline derivative disclosed in US 5,147,875;
a phenylpyrimidone derivative disclosed in US 5,118,686;
an imidazoquinoxalinone derivative or its aza analog disclosed in US
5,055,465 and 5,166,344;
a phenylpyrimidone derivative disclosed in US 5,290,933;
a 4-aminoquinazoline derivative disclosed in US 5,436,233 or 5,439,895;
a 4,5-dihydro-4-oxo-pyrrolo[1,2-a]quinoxaline derivative disclosed in US
5,405,847;
a polycyclic guanine derivative disclosed in US 5,393,755;
a nitogenous heterocyclic compound disclosed in US 5,576,322;
a quinazoline derivative disclosed in US 4,060,615;
a 6-heterocyclyl pyrazolo[3,4-d]pyrimidin-4-one disclosed in US 5,294,612;
and a 4-aminoquinazoline derivative disclosed in US 5,436,233;
Other disclosures of cGMP PDE inhibitors include:
European patent application (EPA) publication no. 0428268;
European patent 0442204;
International patent application publication no. WO 94/19351;
Japanese patent application 5-222000;
European Journal of Pharmacology, 251, (1994), 1;
International patent application publication no. WO 94/22855;
a pyrazolopyrimidine derivative disclosed in European patent application 0636626;
a 4-aminopyrimidine derivative disclosed in European patent application 0640599;
an imidazoquinazoline derivative disclosed in International patent application W095/06648;
an anthranilic acid derivative disclosed in International patent application W095/18097;
a tetracyclic derivative disclosed in International patent application W095/19978;
an imidazoquinazoline derivative as disclosed in European patent application 0668280; and a quinazoline compound disclosed in European patent application 0669324.
The cGMP PDE inhibition of a compound can be determined by standard assays known to the art, for example as disclosed in US 5,250,534. Compounds that are selective inhibitors of cGMP PDE relative to cAMP PDE are preferred, and determination of such compounds is also taught in US 5,250,534. Particularly preferred are compounds that selectively inhibit the PDEv isoenzyme, as disclosed in WO 94/28902.
In addition, an estrogen agonist / antagonist can be used in combination with antibiotics such as azithromycin and/or antifungals such as fluconazole and vorconazole. Such combinations are particularly useful for treating vaginal or urinary bacterial or yeast infections.
The additional compounds that can be administered with an estrogen agonist / antagonist can be administered in the same dosage form or in different dosage forms. Likewise, the additional compounds can be administered at the same time as the estrogen agonist /antagonist or at different times. All combinations of dosage form and times are contemplated.
It is also noted that an estrogen agonist / antagonist can be administered using a topical dosage form such as a patch that is placed on the skin or an ointment that is rubbed on the skin. Such a dosage form can be used to administer other compounds that can be used in combination with an estrogen agonist /
antagonist. In one embodiment, the estrogen agonist / antagonist is administered in combination with one or more additional compounds. In another embodiment, the additional compounds are administered using a topical dosage form and the estrogen agonist antagonist is administered using a different dosage form such as a tablet.
The methods of measuring vaginal health involve an evaluation of vaginal health symptoms and a physical examination to determine physiological markers of vaginal health. The methods may also include a measurement of vaginal and/or urinary tract infection frequency and/or frequency of urinary incontinence.
The evaluation of pathological vaginal symptoms and subject-perceived vaginal health status is self-evaluated by the subject.
Measurements that are made during a gynecological examination include a vaginal pH measurement and a determination of vaginal maturation index.
Vaginal pH measurements are performed first during an examination and always prior to vaginal maturation index measurement or a PAP smear. If, at the beginning of the examination, a significant amount of lubricant is required to insert the speculum, the pH may be measured prior to the insertion of the speculum.
Vaginal pH measurements may be made with a single use, disposable pH
probe such as the pHem-AIertT"" pH probe (Imagyn Medical Technologies, Inc., Costa Mesa, CA). The pH probe is removed from packaging, inserted into the outer 1/3 of the vagina, and held against the lateral sidewall for about 2 seconds to moisten the paper. Contact between the pH probe and blood or cervical mucous should be avoided as the pH of these substances is generally neutral. The pH
probe is then removed and immediately compared to the pH color chart accompanying the pH probe to determine the pH of the vagina.
The vaginal maturation index represents the degree of proliferation and maturation of vaginal cells. The results are reported as percentages of parabasal, intermediate, and superficial cells as determined by techniques known in the art.
The vaginal maturation index smear must be taken prior to the PAP smear. A
commercially available kit for cytological specimen collection may be used (PAP
PakT"", Medical Packaging Corp., Camarillo, CA) to obtain the maturation index specimen. Generally, a rounded spatula end is used to take a gentle scraping from the mid-third lateral area of the vagina and applied to a microscope slide.
The sample must not be taken from the cervix or any other area of the vagina. The sample must also be collected from a healthy area free from inflammation, infection, ulceration, debris, or other contaminants. The preparation is immediately fixed by flooding the entire slide with standard cytology fixative. The fixative may be a standard fixative for cytology specimens such as that included in the PAP
PakT""
specimen collection kit. Once the fixative has dried, the specimen is evaluated microscopically and the maturation index determined.
The subject self-assessment of vaginal health is performed with a subjective vaginal health questionnaire. Typically, the questionnaire is performed in private and the results kept confidential. The questionnaire may include an envelope that is specially encoded to later identify the treatment that the subject is undergoing.
Examples of the questions and the ratings for questions are shown in Table 1.
An additional question may be added in subsequent questionnaires following administration of the baseline questionnaire, which question would ask: "Have you had any positive or negative vaginal changes since you have been taking the study medication?" This question may be coupled to a multiple-point ratings scale ranging from "mostly positive changes," to "moderately positive changes," to "mildly positive changes," to "no changes," to "mildly negative changes," to "moderately negative changes," to "mostly negative changes."
Table 1 : Subjective Vaginal Health Questionnaire Questions Question Select Response or Report Number How many children haveNatural Delivery?
you had 1 by: Cesarean Section?
How many vaginal infections have you had in the last 6 months?
How many urinary tract infections have you had in the last 6 months?
a) No Leakage (never use protection)?
b) Mild Leakage (no protection necessary)?
c) Moderate Leakage (occasionally wear What is the severity of any urinary protection)?
incontinence that you d) Moderately Severe Leakage (regularly wear experience?
protection)?
e) Severe Leakage (must change protection more than 2 times per day)?
a) When laughing, coughing, straining or If you experience any physically active?
amount of urinary incontinence, b) Leakage is uncontrollable and when does is preceded by it occur? a strong urge or need to urinate.
c) Leakage occurs without apparent cause.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal closely represents dryness and 7 representing extreme your degree of vaginal vaginal dryness? dryness.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal closely represents itching or irritation and 7 representing your degree of extreme vaginal itching or vaginal itching or irritation.
irritation?
Are you taking any products to g assist with vaginal dryness, irritation or itching?
What is your overall No Problems.
vaginal health. Mild Problems.
Question Select Response or Report Number Moderate Problems.
Moderately Severe Problems.
Severe Problems.
a) None What is the occurrence b) Rare (less than 1 per month) and frequency of any type c) Infrequent (1-3 times per of sexual month) activity? d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) a) None What is the occurrence b) Rare (less than 1 per month) of orgasm 11 (bY any means) with c) Infrequent (1-3 times per sexual month) activity? d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) Has anything happened in your (e~g~> change in health status or change in 12 personal life to decreaserelationships, etc.) your interest in sexual activity?
When the present assessment of vaginal nealtn metnoas are usea to evaluate drug efficacy or efficacy of other therapeutic methods, a vaginal health evaluation is made at the beginning of treatment. An additional evaluation is made one or more times during the course of or at the end of treatment such as every six 5 manths during the course of the study.
An important aspect of the present invention is the standardized assessment of pelvic organ prolapse and pelvic floor dysfunction. The present method can use a standardized system of terminology and grading from Baden, W.
and Walter, T., Surgical Repair of Vaginal Defects, Philadelphia, JB
Linnincott, 10 1992 and Bump, R.C. et al., The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction, Am. J. Obstet. Gynecol. 175:10-17, 1996.
Exam variables are controlled so that accurate measurements may be made over the period of observation that may range anywhere from 6 months to 2 years or more. It is important, therefore, that certain examination variables be held constant for the duration such as: (i) position of the subject during examination; (ii) type of exam table or chair; (iii) type of specula or retractors; (iv) type of straining (Valsalva maneuver or cough); (v) fullness of bladder (void prior to exam);
and (vi) content of rectum (is stool present on rectal exam?).
Vaginal prolapse is graded on a 0 to 4 scale for the following types of prolapse: anterior wall urethrocele; anterior wall cystocele; superior wall uterine prolapse, posterior wall enterocele; and posterior wall rectocele. All prolapses are assigned a grade as determined in Table 2.
Table 2: Conditions Corresponding to Prolapse Grade Grade Criteria for Assigning Grade Normal position inside the mid-vaginal axis for anterior posterior wall Grade 0 prolapse and above the ischial spines for cervical or vaginal cuff. By definition, the most apical point is -3 cm superior to the hymen.
If the prolapse crosses the respective thresholds, and descends halfway Grade 1 to the hymen.
Grade 2 Descent to the hymen.
Grade 3 Descent 2 cm beyond the hymen.
Maximum possible descent for each site. A complete eversion is -5 cm Grade 4 .
beyond the hymen.
For quantitation of pelvic organ position and prolapse, the totlowing conditions apply: (i) the prolapse must be evaluated relative to a fixed point of reference; (ii) the ischial spines are reference for cervix or vaginal cuff prolapse; (iii) the vaginal midline axis will serve as a landmark for anterior and posterior wall prolapse; and (iv) the hymen will be the landmark for any prolapse extending beyond the ischial spines or the vaginal midline axis. The procedure for visualization of the prolapse is as follows:
(1 ) If an enterocele is suspected or the grade is uncertain, the examination is performed while the subject is standing.
(2) A posterior speculum blade or fingers are inserted to the vaginal apex, perineum is depressed, strain elicited, and withdrawal accomplished slowly to observe for prolapse and grade.
(3) The procedure is repeated by moving the speculum anteriorly to grade enterocele and rectocele if enterocele and rectocele are inadequately visualized in (2) above.
Finally, external urogenital measurements are made in centimeters. As the propensity of pelvic prolapse increases as the ratio of genital hiatus to perineal body measurement increases, the genital hiatus and perineal body are measured as follows:
Genital hiatus: Distance from the middle of the external meatus to the posterior mid-line hymen.
Perineal body: Distance from the posterior margin of the genital hiatus to the mid-anal opening.
During the examination for pelvic organ prolapse and pelvic floor dysfunction, objective measurements may also be made to evaluate the subject's vaginal health. These measurements may include measurements of blood estrogen and testosterone levels, measurement of vaginal pH, and measurement of the vaginal maturation index.
An internal vaginal health evaluation may be performed with continuously variable scale used under the following guidelines: The examiner is presented with a printed line of between 3 and 20 centimeters in length, preferably between 6 and 15 centimeters in length and most preferably 10 centimeters in length. The line is scaled with axis markers corresponding to degrees of internal vaginal health.
For example, on a horizontal line, 10 centimeters in length, one end of the line may be marked with the numeral (I), the midpoint of the line marked with the numeral (II) and the end of the line opposite of numeral (I) is marked with the numeral (III). The numerals I-III are indicated to correspond to the following condition:
(I) No rugae, elasticity non-existent, friable and bleeds to the touch, mucosa very pale, very dry, stenotic, narrow vaginal apex.
(II) Few rugae, mild elasticity, mucosa pale in color (not pink), loss of some moisture, slightly stenotic, mild narrowing of vaginal apex.
(III) Rugae present, good elasticity, pink, roboust mucosa, good vaginal moisture, normal vaginal apex with good depth.
The examiner is instructed to place a mark on the line representing the continuum of vaginal conditions from numerals I-III that best describes the internal evaluation.
In addition to the internal evaluation, an external evaluation may be obtained describing, for example, the appearance of pubic hair (i.e. very scant, scant, moderate, normal, excessive) and the condition of the labia (i.e. full thickness, mild vulWar regression, moderate vulvar regression (atrophic labia) or labial fusion (severe atrophy)).
i i The data obtained from the vaginal examination and tests described above are used in their totality to assess the vaginal health of a patient. The methods can be used to determine if a compound that has been administered to a patient has affected vaginal health, or the methods can be used to help a clinician assess vaginal health for the purpose of making a diagnosis. The present methods can also be used to assess changes in vaginal heath over time.
Interestingly, through the use of a self-assessment questionnaire, it has been found that postmenopausal women taking the estrogen agonist/antagonist (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd ro-naphthalene-2-0l, D-tartrate salt reported an increased frequency of sexual intercourse and/or an increased number of orgasms and/or increased intensity of orgasms.
The examples set forth below are intended to illustrate specific embodiments of the present invention and are not intended to limit the scope of the specification, including the claims, in any manner. , EXAMPLES
Example 1: Improvement or Maintenance of UroQenital Health.
Effects of estrogen agonists / antagonists for improving or maintaining urogenital health are assessed in a patient population of postmenopausal women not undergoing hormone replacement therapy. The efficacy of the estrogen agonist/antagonist for improving or maintaining urogenital health is measured in a random, double-blind, placebo controlled clinical study.
Patients are randomly separated into either a treatment group or a placebo group. Patients are initially given a subjective vaginal health questionnaire before receiving placebo or estrogen agonist / antagonist. Treatment or placebo is initiated and continued for 6 months. The questionnaire is administered to all patients at 3 and 6 months.
The patient self-assessment of vaginal health is performed with a subjective vaginal health questionnaire. The questionnaire is performed in private and the results kept confidential. The questionnaire is specially encoded to later identify the treatment that the patient is undergoing. Examples of the questions are given in Table 1. An additional question is added in subsequent questionnaires following the baseline questionnaire which would ask: "Have you had any positive or negative vaginal changes since you have been taking the study medication?" This question is coupled to a multiple-point ratings scale ranging from "mostly positive changes,"
to "moderately positive changes," to Nmildly positive changes," to "no changes," to "mildly negative changes," to "moderately negative changes," to "mostly negative changes.°
Table 1 : Subjective Vaginal Health Questionnaire Questions Question Select Response How many children haveNatural Delivery?
you had by: Cesarean Section?
How many vaginal infections have you had in the last 6 months?
How many urinary tract infections 3 have you had in the last 6 months?
a) No Leakage (never use protection)?
b) Mild Leakage (no protection necessary)?
c) Moderate Leakage (occasionally wear What is the severity of any urinary protection)?
4 incontinence that you d) Moderately Severe Leakage (regularly wear experience?
protection)?
e) Severe Leakage (must change protection more than 2 times per day)?
a) When laughing, coughing, straining or If you experience any physically active?
amount of 5 urinary incontinence, b) Leakage is uncontrollable and when does is preceded by it occur? a strong urge or need to urinate.
c) Leakage occurs without apparent cause.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal 6 closely represents dryness and 7 representing extreme your degree of vaginal vaginal dryness? dryness.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal 7 closely represents itching or irritation and 7 representing your degree of extreme vaginal itching or vaginal itching or irritation.
irritation?.
Are you taking any products to 8 assist with vaginal dryness, irritation or itching?
Question Select Response No Problems.
Mild Problems.
What is your overall vaginal g Moderate Problems.
health.
Moderately Severe Problems.
Severe Problems.
a) None What is the occurrenceb) Rare (less than 1 per month) and frequency of any type c) Infrequent (1-3 times per month) of sexual activity? d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) a) None What is the occurrenceb) Rare (less than 1 per month) of orgasm 11 (by any means) with c) Infrequent (1-3 times per month) sexual activity? ' d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) Has anything happened in your (e~g~~ change in health status or change in 12 personal life to decrease your relationships, etc.) interest in sexual activity?
4) the degree of vaginal dryness;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient.
Also provided are methods for assessing vaginal health in a patient, the methods comprising:
a) conducting a gynecological examination that comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length; and assessing the quantity of pubic hair and the thickness of the vulva;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index ;
d) determining vaginal prolapse using the following scale:
Grade normal position inside the mid-vaginal axis for 0 anterior posterior wall prolapse and above the ischial spines for cervical or vaginal cuff. By definition, the most apical point is -3 cm superior to the hymen.
Grade if the prolapse crosses the respective thresholds 1 and descends halfway to the hymen Grade descent to the hymen Grade descent 2 cm beyond the hymen Grade maximum possible descent for each site. A complete 4 eversion is about 5 cm beyond hymen.
e) administering a questionnaire to the patient, the questionnaire comprising questions relating to:
1 ) the number of vaginal infections in a specified time period;
2) the number of urinary infections in a specified time period;
3) the amount of urinary leakage in a specified time period;
4) the degree of vaginal dryness in a specified time period;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient;
and f) measuring plasma levels of estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
n i DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to drugs and kits for improving or maintaining urogenital health. Specifically, the invention relates to drugs of lowering vaginal pH, treating urinary tract infections, treating vaginal dryness, treating vaginal itching, treating undesired vaginal spasms, treating vaginitis, treating vaginal yeast or bacterial infections, treating vulvar atrophy, treating urethrocele, cystocele, rectocele, or enterocele prolapse, treating urinary or anal incontinence, treating undesired urinary frequency or urgency, and increasing the frequency and intensity of orgasms. The present invention also relates to methods for assessing vaginal health, which are useful for determining the efficacy and safety of new pharmaceutical substances and compositions that affect the vagina and for making diagnostic decisions.
As used herein, the terms "treat", "treatment" and "treating" include preventative (e.g., prophylactic) and palliative treatment of the disease or condition, or amelioration of a symptom of the disease or condition.
The phrase Nmaintaining or improving urogenital health" means the prevention of pathological urogenital conditions or symptoms of the conditions or a slowing of the processes underlying the conditions or the development of the symptoms of the conditions or a reversal of the conditions or a reversal of the symptoms of the conditions. An improvement in urogenital health may include a reduction in the urogenital infections, including vaginal and urinary infections; a reduction in vaginal dryness, itching and irritation; and/or a reduction of incontinence. An improvement in urogenital health may also include the maintenance or improvement of pelvic floor integrity, which includes prolapse.
The term "incontinence" includes urinary and anal incontinence. When the incontinence is urinary in nature, it is defined as involuntary urine loss that is a social or hygienic problem. Urinary incontinence may be stress incontinence, urge incontinence or mixed incontinence which is stress and urge incontinence occurring together, or it may be unconscious incontinence which occurs without urgency and without conscious recognition of leakage. There may be hesitancy, straining to void, poor stream as indicated by a decreased force of flow of the urinary stream.
Intermittent stream may be noted as a "stop and start" pattern of urination.
Or there may be incomplete emptying of the bladder or postmicurition dribble that is urine loss occurring just after normal urination has been completed.
"Anal incontinence" is the involuntary loss of feces or flatus that may be caused by rectal prolapse. Normally, the rectum is attached firmly to the levator ani muscle complex through an extensive interweaving of longitudinal muscle fibers.
These attachments are important because the rectum undergoes multiple changes in position and location during the act of normal defecation. Without this attachment, the rectum would slip down through the levator muscle hiatus during defecation. In rectal prolapse, this occurs.
A "prolapse" is a downward or forward displacement of one of the pelvic organs from its normal location. Traditionally, prolapse has referred to displacement of the bladder, the uterus, or rectum. Prolapse can also relate to displacement of the vagina. These displacements have usually been graded on a scale of 0-4; the grade increases with increasing severity of the prolapse. A
variety of terms are used to describe female genital prolapse that have been fixed in the literature, which terms include:
A "cystocele" is a downward displacement of the bladder.
A "cystourethocele" is a cystocele that includes the urethra as part of the prolapsing organ complex.
A "uterine prolapse" is descent of the uterus and cervix down the vaginal canal toward the vaginal introitus.
A "rectocele" is a protrusion of the rectum into the posterior vaginal lumen.
A "enterocele° is a herniation of the small bowel into the vaginal lumen.
The term "vaginitis" means inflammation of the vagina.
The phrase "undesired urinary frequency or urgency" means that a patient urinates more often than an average of a group of similar patients. Typically, this increased number of urinations makes the patient psychologically uncomfortable and is embarrassing. In addition, a patient can experience an enhanced sense of the need to urinate when compared with a similar group. This heightened sense of needing to urinate can also lead to psychological discomfort and embarrassment.
The term "increasing the frequency or intensity of orgasms" means that a patient experiences more orgasms or experiences or perceives a heightened intensity of orgasms after treatment with the present compounds than without treatment. A way to measure a patient's perception of increased number of orgasms and/or increased intensity of orgasms is to ask the patient. For example, a questionnaire can be used.
Some aspects of vaginal health status can be determined by analysis of vaginal secretions. Normal vaginal secretions are floccular in consistency, white in color, and usually located in the dependent portion of the vagina (posterior fomix).
Vaginal secretions can be analyzed by a wet-mount preparation. A sample of vaginal secretions is suspended in 0.4 mL of normal saline in a glass tube, transferred to a slide, covered with a slip, and assessed by microscopy. Some clinicians prefer to prepare slides by suspending secretions in saline placed directly on the slide.
Secretions should not be placed directly on the slide without saline because this method causes drying of the vaginal secretions and does not result in a well-suspended preparation. Microscopy of normal vaginal secretions reveals many superficial epithelial cells, a few white blood cells (less than one per epithelial cell), and few, if any, clue cells. Clue cells are superficial vaginal epithelial cells with adherent bacteria, usually G. vaginalis, which obliterates the crisp cell border and usually can be visualized microscopically. Potassium hydroxide 10% (KOH) may be added to the slide, or a separate preparation can be made, to examine the secretions for fungal elements. The results should be negative for women with normal vaginal microbiology. Gram stain will reveal that normal superficial epithelial cells appear normal and a predominance of gram positive rods (lactobacilli).
The phrase "adverse effects associated with estrogen" include breast tenderness, bloating, headache, increased blood clotting and menstrual bleeding in women and breast cancer. Estrogen therapy increases the risk of endometrial carcinoma. Women on long-term estrogen therapy may have an increased risk that is got reversed by concurrent administration of progestin (N Engl J Med 195;332:1589).
The term "postmenopausal women" is defrned to include not only women of advanced age who have passed through menopause, but also women who have been hysterectomized or for some other reason have suppressed estrogen production, such as those who have undergone long-term administration of corticosteroids, suffer from Cushings' syndrome, have gonadaf dysgenesis or who have undergone radiation therapy.
"Breast cancer" is defined as a malignant proliferation of epithelial cells lining the ducts or lobules of the breast.
The term "patient" means animals, particularly mammals. Preferred patients are humans, with postmenopausal female humans being the most preferred patients.
An "estrogen agonist / antagonist" is a compound that affects some of the same receptors that estrogen does, but may not affect all, and in some instances, it antagonizes or blocks estrogen. It is also known as a "selective estrogen receptor modulator" (SERM). Estrogen agonists / antagonists may also be referred to as antiestrogens although they have some estrogenic activity at some target tissues.
Estrogen agonists / antagonists are therefore not what are commonly referred to as "pure antiestrogens". Antiestrogens that can also act as agonists are referred to as Type I antiestrogens. Type I antiestrogens activate the estrogen receptor to bind tightly in the nucleus for a prolonged time but with impaired receptor replenishment (Clark, et al., Steroids, 1973;22:707, Capony et al., Mol Cell Endocrinol, 1975;3:233).
When a woman reaches menopause, changes in the urogenital system can occur. These changes include increased vaginal pH; increased number of vaginal yeast and bacterial infections, which can be exacerbated by increased vaginal pH;
increased vaginal dryness and itching; undesired vaginal spasms; vaginitis;
vulvar atrophy; various types of prolapse as described herein; and urinary or anal incontinence, which can be the result of a prolaspse. In accordance with the present invention, these conditions can be treated by administering an estrogen agonist / antagonist. By treating these conditions, the overall vaginal health of a patient is maintained or improved.
The estrogen agonists / antagonists of the invention may be administered systemically or locally. For systemic use, the estrogen agonists / antagonists herein are formulated for parenteral (e.g., intravenous, subcutaneous, intramuscular, intraperitoneal, intranasal or transdermal) or enteral (e.g., oral or rectal) delivery according to conventional methods. Intravenous administration can be by a series of injections or by continuous infusion over an extended period.
Administration by injection or other routes of discretely spaced administration can be performed at intervals ranging from monthly, weekly to once to three or more times daily.
Another method of administering compounds of the present invention includes the use of topical dosage forms. For example, the active agent can be administered to a patient in a cream or ointment that is applied to the skin, particularly the skin of the vagina. Alternatively, the active agent can be delivered using a patch that is applied to the skin. The use of a topical dosage form is particularly useful in treating vaginal dryness, urinary and/or vaginal bacterial or yeast infections and dyspureunia.
Preferred estrogen agonists / antagonists that can be used in the methods and kits of the present invention include the compounds described in U.S.
patent number 5,552,412. Those compounds are described by the formula designated herein as formula (I) given below:
~Y U) HO-a wherein:
A is selected from CH2 and NR;
B, D and E are independently selected from CH and N;
Y is (a) phenyl, optionally substituted with 1-3 substituents independently selected from R4;
(b) naphthyl, optionally substituted with 1-3 substituents independently selected from R4;
(c) C3-Ca cycloalkyl, optionally substituted with 1-2 substituents independently selected from R4;
(d) C3-C8 cycloalkenyl, optionally substituted with 1-2 substituents independently selected from R4;
(e) a five membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)~-, optionally substituted with 1-3 substituents independently selected from R4;
2'-G
t (f) a six membered heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NR2- and -S(O)n- optionally substituted with 1-3 substituents independently selected from R4; or (g) a bicyclic ring system consisting of a five or six membered heterocyclic ring fused to a phenyl ring, said heterocyclic ring containing up to two heteroatoms selected from the group consisting of -O-, -NRZ- and -S(O)S , optionally substituted with 1-3 substituents independently selected from R4;
Z' is (a) -(CH2)P W(CHZ)q-;
(b) -O(CH2)P CR5R6-;
(c) -O(CH2)PW(CH2)q-;
(d) -OCHR2CHR3-; or (e) -SCHR2CHR3-;
G is (a) -NR'R8;
(b) N ~ (CH2)m'~Z2 ~(CH2)n-"~
wherein n is 0, 1 or 2; m is 1, 2 or 3; Z2 is -NH-, -O-, -S-, or -CH2-;
optionally fused on adjacent carbon atoms with one or two phenyl rings and, optionally independently substituted on carbon with one to three substituents and, optionally, independently on nitrogen with a chemically suitable substituent selected from R4; or (c) a bicyclic amine containing five to twelve carbon atoms, either bridged or fused and optionally substituted with 1-3 substituents independently selected from R4; or Z' and G in combination may be N
-OCHz ()n , W IS
(a) -CHz-;
(b) -CH=CH-;
_O-;
(d) -NRZ-;
(e) -S(O)n-, O
(f) -C
(g) -CRZ(OH)-;
(h) -CONRZ-;
(i) -NR2C0-;
G) ; or (k) -C--__C-;
R is hydrogen or C~-C6 alkyl;
R2 and R3 are independently (a) hydrogen; or (b) C,-C4 alkyl;
R4 is (a) hydrogen;
(b) halogen;
(c) C~-C6 alkyl;
(d) C,-C4 alkoxy;
(e) C,-C4 acyloxy;
(f) C,-C4 alkylthio;
(g) C,-C4 alkylsulfinyl;
(h) C~-C4 alkylsulfonyl;
(i) hydroxy (C~-C4)alkyl;
(j) aryl (C,-C4)alkyl;
(k) -C02H;
(I) -CN;
(m) -CONHOR;
(n) -SOZNHR;
(o) -NHZ;
(p) C,-C4 alkylamino;
(q) C,-C4 dialkylamino;
(r) -NHS02R;
(s) -N02;
(t) -aryl; or (u) -OH;
R5 and R6 are independently C,-C8 alkyl or together form a C3-C,o carbocyclic ring;
R' and R$ are independently (a) phenyl;
(b) a C3-C,o carbocyclic ring, saturated or unsaturated;
(c) a C3-C,o heterocyclic ring containing up to two heteroatoms, selected from -O-, -N- and -S-;
(d) H;
(e) C,-C6 alkyl; or (f) form a 3 to 8 membered nitrogen containing ring with R5 or R6;
R' and Ra in either linear or ring form may optionally be substituted with up to three substituents independently selected from C,-C6 alkyl, halogen, alkoxy, hydroxy and carboxy;
a ring formed by R' and R$ may be optionally fused to a phenyl ring;
a is 0, 1 or 2;
m is 1, 2 or 3;
n is 0, 1 or 2;
p is 0, 1, 2 or 3;
q is 0, 1, 2 or 3;
and optical and geometric isomers thereof; and nontoxic pharmacologically acceptable acid addition salts, N-oxides, esters, quaternary ammonium salts and prodrugs thereof.
Additional preferred compounds of the invention also disclosed in U.S.
patent number 5,552,412 are described by the formula designated herein as formula (IA):
OCH~CH~G
HG
(IA) -N~ ~ or -N
wherein G is ' /N
R' is H, OH, F, or CI; and B and E are independently selected from CH
and N, and pharmaceutically acceptable salts thereof.
Especially preferred compounds for the methods of the invention are:
cis-6-(4-fluoro-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
(-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd ro-naphthalene-2-ol;
cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7, 8-tetrahyd ro-naphthalene-2-ol;
cis-1-[6'-pyrrolidinoethoxy-3'-pyridyl]-2-phenyl-6-hydroxy-1,2,3,4-tetrahydronaphthalene;
1-(4'-pyrrolidinoethoxyphenyl)-2-(4"-fluorophenyl)-6-hydroxy-1,2,3,4-tetrahydroisoquinoline;
cis-6-(4-hydroxyphenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol;
1-(4'-pyrrolidinoethoxyphenyl)-2-phenyl-6-hydroxy-1,2,3,4-tetrahydroisoquinoline; and pharmaceutically acceptable salts thereof. An especially preferred salt of (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of is the D-tartrate salt.
The syntheses of compounds of formula (I) are set forth in U.S. patent number 5,552,412.
Other preferred estrogen agonists / antagonists are disclosed in U.S. patent number 5,047,431. The structure of these compounds are described by the formula designated herein as formula (II) below:
OCH~CH~N, OH
wherein R'A and R~'' may be the same or different and are either H, methyl, ethyl or a benzyl group; and optical or geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof. A particularly preferred compound is droloxifene. The syntheses of the compounds of formula (II) are set forth in U.S. patent number 5,047,431 Additional preferred estrogen agonists / antagonists are tamoxifen:
(ethanamine,2-[-4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl, (Z)-2-, 2-hydroxy-1,2,3-propanetricarboxylate(1:1)) and other compounds as disclosed in U.S.
patent number 4,536,516; 4-hydroxy tamoxifen (i.e., tamoxifen wherein the 2-phenyl moiety has a hydroxy group at the 4 position) and other compounds as disclosed in U.S.
patent number 4,623,660; raloxifene: (methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl][4-[2-(1-piperidinyl)ethoxy]phenyl]-,hydrochloride) and other compounds as disclosed in U.S. patent numbers 4,418,068; 5,393,763;
5,457,117; 5,478,847 and 5,641,790; toremifene: (ethanamine, 2-[4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) and other compounds as disclosed in U.S. patent numbers 4,696,949 and 4,996,225; centchroman: 1-[2-[[4-(-methoxy-2,2, dimethyl-phenyl-chroman-4-yl)-phenoxy]-ethyl]-pyrrolidine and other compounds as disclosed in U.S. Patent 3,822,287; idoxifene: pyrrolidine, 1-[-[4-[[1-(4-iodophenyl)-2-phenyl-1-butenyl]phenoxy]ethyl] and other compounds as disclosed in U.S. patent number 4,839,155; 6-(4-hydroxy-phenyl)-5-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-naphthalen -2-0l and other compounds as disclosed in U.S. patent number 5,484,795; and {4-[2-(2-aza-bicyclo[2.2.1 ]hept-2-yl)-ethoxy]-phenyl}-[6-hydroxy-2-(4-hydroxy-phenyl)-benzo[b]thiophen-3-yl]-methanone and other compounds as disclosed in published international patent application WO 95/10513.
Further preferred estrogen agonists / antagonists include EM-652 (as shown in the formula designated herein as formula (ill) and EM-800 (as shown in the formula designated herein as formula (IV)). The synthesis of EM-652 and EM-800 and the activity of various enantiomers is described in Gauthier et al., J.
Med. Chem., 1997;40:2117-2122.
(III) N
O
H C \CH3 (IV) Further preferred estrogen agonists / antagonists include TSE 424 and other compounds disclosed in U.S. patent number 5,998,402, U.S. patent number 5,985,910, U.S. patent number 5,780,497, U.S. patent number 5,880,137, and European patent application EP 0802183 A1 including the compounds described by the formulae designated herein as formulae V and VI, below:
XA Rse RIB
(v) Rze R.
A
O
C
xA R3B
R,B \
RaB
/, N \
RzB
Hz)s YA
wherein:
R,B is selected from H, OH or the C,-C~2 esters (straight chain or branched) or C,-C~2 (straight chain or branched or cyclic) alkyl ethers thereof, or halogens; or C,-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether;
RZB, R3g, RaB, R5B, and ReB are independently selected from H, OH or the C,-C~2 esters (straight chain or branched) or C,-C~2 alkyl ethers (straight chain or branched or cyclic) thereof, halogens, or C,-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether, cyano, C~-Cg alkyl (straight chain or branched), or trifluoromethyl;
XA is selected from H, C~-C6 alkyl, cyano, vitro, trifluoromethyl, and halogen;
s is 2 or 3;
YA is selected from:
a) the moiety:
\ iR~B
Rae wherein R,B and R8B are independently selected from the group of H, C~-Cs alkyl, or phenyl optionally substituted by CN, C~-Cs alkyl (straight chain or branched), C~-Cs alkoxy (straight chain or branched), halogen, -OH, -CF3, or -OCF3;
b) a five-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C~-Ca alkyl)-, -N=, and -S(O)S , wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C~-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H-, -CN, -CONHR,B, -NH2, C,-C4 alkylamino, di(C,-C4)alkylamino, -NHS02R,B, -NHCOR~B; -N02, and phenyl optionally substituted with 1-3 (C,-C4)alkyl;
c) a six-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C,-C4 alkyl)-, -N=, and -S(O)S , wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C~-C4 alkoxy, trihalomethoxy, C~-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C~-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR~B-, -NH2, C,-Cq alkylamino, di(C,-C4)alkylamino, -NHS02R,B, -NHCOR,B, -NOZ, and phenyl optionally substituted with 1-3 (C,-C4)alkyl;
d) a seven-membered saturated, unsaturated or partially unsaturated heterocycle containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C~-C4 alkyl)-, -N=, and -S(O)~-, wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C~-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C~-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -COZH, -CN, -CONHR~B, -NH2, C,-C4 alkylamino, di(C~-C4)alkylamino, -NHSOZR~$, -NHCOR~B, -NOZ, and phenyl optionally substituted with 1-3 (C,-C4)alkyl; or e) a bicyclic heterocycle containing from 6-12 carbon atoms either bridged or fused and containing up to two heteroatoms selected from the group consisting of -O-, -NH-, -N(C~-C4 alkyl)-, and -S(O)S , wherein a is an integer of from 0-2, optionally substituted with 1-3 substituents independently selected from the group consisting of hydrogen, hydroxyl, halo, C,-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C1-C4 acyloxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONHR,B, -NH2, -N=, C,-C4 alkylamino, di(C~-C4)alkylamino, -NHS02R,B, -NHCOR,e, -N02, and phenyl optionally substituted with 1-3 (C,-C4) alkyl; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.
The more preferred compounds of this invention are those having the general structures V or VI, above, wherein:
R,B is selected from H, OH or the C,-C,2 esters or alkyl ethers thereof, and halogen;
RZB, R3B, R4B, R5B, and RgB are independently selected from H, OH or the C~-C~2 esters or alkyl ethers thereof, halogen, cyano, C,-Cs alkyl, or trihalomethyl, preferably trifluoromethyl;
XA is selected from H, C,-CB alkyl, cyano, vitro, trifluoromethyl, or halogen;
YA is the moiety:
\ iR~e N
RIB and R$B are selected independently from H, C,-Cg alkyl, or combined by -(~H2)w , wherein w is an integer of from 2 to 6, so as to form a ring, the ring being optionally substituted by up to three substituents selected from the group of hydrogen, hydroxyl, halo, C~-C4 alkyl, trihalomethyt, C~-C4 alkoxy, trihalomethoxy, C~-C4 alkylthio, C,-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONH(C,-C4), -NH2, C,-C4 alkylamino, C~-C4 dialkylamino, -NHS02(C~-C4), -NHCO(C,-C4), and -N02; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.
The rings formed by a concatenated Rye and RaB, mentioned above, may include, but are not limited to, aziridine, azetidine, pyrrolidine, piperidine, hexamethyleneamine or heptamethyleneamine rings.
The most preferred compounds of structural formulas V and VI, above, are those wherein RIB is OH; R28 - RsB are as defined above; XA is selected from the group of CI, N02, CN, CF3, or CH3; YA is the moiety N
Ree and R,B and R8B are concatenated together as -(CH2)t-, wherein t is an integer of from 4 to 6, to form a ring optionally substituted by up to three subsituents selected from the group of hydrogen, hydroxyl, halo, C~-C4 alkyl, trihalomethyl, C,-C4 alkoxy, trihalomethoxy, C,-C4 alkylthio, C~-C4 alkylsulfinyl, C,-C4 alkylsulfonyl, hydroxy (C,-C4)alkyl, -C02H, -CN, -CONH(C,-C4)alkyl, -NHz, C,-C4 alkylamino, di(C~-C4)alkylamino, -NHS02(C,-C4)alkyl, -NHCO(C,-C4)alkyl, and -N02; and optical and geometric isomers thereof; and pharmaceutically acceptable salts, N-oxides, esters, quaternary ammonium salts, and prodrugs thereof.
In a preferred embodiment, the compound is TSE-424 as described by the formula designated herein as formula (Va) below:
OH
H
(Va) The syntheses of compounds of formulas V, Va and VI are set forth in U.S.
patent number 5,998,402. The pharmaceutically acceptable salts of the estrogen agonists / antagonists of this invention may be formed of the compound itself, or of any of its esters, and include the pharmaceutically acceptable salts which are often used in pharmaceutical chemistry. For example, salts may be formed with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfonic acids including such agents as naphthalenesulfonic, methanesulfonic and toluenesulfonic acids, sulfuric acid, nitric acid, phosphoric acid, tartaric acid, pyrosulfuric acid, metaphosphoric acid, succinic acid, formic acid, phthalic acid, lactic acid and the like, most preferable with hydrochloric acid, citric acid, benzoic acid, malefic acid, acetic acid or propionic acid.
The estrogen agonists / antagonists of this invention, as discussed above, can be administered in the form of pharmaceutically acceptable salts. The salts are conveniently formed, as is usual in organic chemistry, by reacting the compound of this invention with a suitable acid, such as has been described above. The salts are quickly formed in high yields at moderate temperatures, and often are prepared by merely isolating the compound from a suitable acidic wash as the final step of the synthesis. The salt-forming acid is dissolved in an appropriate organic solvent, or aqueous organic solvent, such as an alkanol, ketone or ester. On the other hand, if the compound of this invention is desired in the free base form, it is isolated from a basic final wash step, according to the usual practice. A preferred technique for preparing hydrochlorides is to dissolve the free base in a suitable solvent and dry the solution thoroughly, as over molecular sieves, before bubbling hydrogen chloride gas through it. A prefer-ed salt of (-)-cis-6-phenyl-5-[4-(2-pyn-olidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-of is the D-(-)-tartrate salt. It will also be recognized that it is possible to administer amorphous forms of the estrogen agonists / antagonists.
The expression "pharmaceutically acceptable salts" includes both pharmaceutically acceptable acid addition salts and pharmaceutically acceptable cationic salts. The expression "pharmaceutically-acceptable cationic salts" is intended to define but is not limited to such salts as the alkali metal salts, (e.g.
sodium and potassium), alkaline earth metal salts (e.g., calcium and magnesium), aluminum salts, ammonium salts, and salts with organic amines such as benzathine (N,N'-dibenzylethylenediamine), choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), benethamine (N-benzylphenethylamine), diethylamine, piperazine, tromethamine (2-amino-2-hydroxymethyl-1,3-propanediol) and procaine. The expression "pharmaceutically-acceptable acid addition salts" is intended to define but is not limited to such salts as the hydrochloride, hydrobromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate, dihydrogenphosphate, acetate, succinate, citrate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts.
One of ordinary skill in the art will recognize that certain estrogen agonists /
antagonists of this invention will contain one or more atoms which may be in a particular stereochemical, tautomeric, or geometric configuration, giving rise to stereoisomers, tautomers and configurational isomers. All such tautomers and isomers and mixtures thereof are included in this invention. Hydrates and solvates of the compounds of this invention are also included.
The subject invention also includes isotopicaily-labeled estrogen agonists /
antagonists, which are structurally identical to those disclosed above, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature.
Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, sulfur, fluorine and chlorine, such as 2H, 3H, '3C, '4C, 'SN, '80, "O, 3'P, ~F, 355, '8F and SCI, respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds and of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically labeled compounds of the present invention, for example those into which radioactive isotopes such as 3H and'4C
are incorporated, are useful in compound and/or substrate tissue distribution assays.
Tr-itiated, i.e., 3H, and carbon-14, i.e., '4C, isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labeled compounds of this invention and prodrugs thereof can generally be prepared by carrying out known or referenced procedures and by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
Certain ester groups are preferred when a compound of this invention contains an ester. The estrogen agonists / antagonists including the compounds of formula I, IA, li, III, IV, V, Va, or VI may contain ester groups at various positions as .y defined herein above, where these groups are represented as -COORS, R9 is C,-C,4 alkyl, C,-Cs chloroalkyl, C,-C3 fluoroalkyl, C5-C~ cycloalkyl, phenyl, or phenyl mono-or disubstituted with C,-C4 alkyl, C,-C4 alkoxy, hydroxy, nitro, chloro, fluoro or tri(chloro or fluoro)methyl.
As used herein, the term "effective amount" means an amount of an estrogen agonist / antagonist or combination of estrogen agonists / antagonists that is capable of treating the described pathological condition. The specific dose of a compound or combination of compounds administered according to this invention will, of course, be determined by the particular circumstances including, for example, the compound or combination administered, the route of administration, and the severity of the pathological condition being treated.
The dose of a compound of this invention to be administered to a patient is rather widely variable and subject to the judgement of the attending physician. It should be noted that it may be necessary to adjust the dose of a compound when it is administered in the form of a salt, such as a laureate, the salt forming moiety of which has an appreciable molecular weight.
The following dosage amounts and other dosage amounts set forth elsewhere in this description and in the appendant claims are for an average human patient having a weight of about 65 kg to about 70 kg. The skilled practitioner will readily be able to determine the dosage amount required for a patient whose weight falls outside the 65 kg to 70 kg range. All doses set forth herein, and in the appendant claims, are daily doses of the free base form of the estrogen agonists /
antagonists.
Calculation of the dosage amount for other forms of the free base form such as salts or hydrates is easily accomplished by performing a simple ratio relative to the molecular weights of the species involved.
The general range of effective administration rates of the estrogen agonists /
antagonists is from about 0.001 mg/daylkg body weight to about 200 mg/day/kg body weight. A preferred rate range is from about 0.010 mg/day/kg body weight to 100 mg/day/kg body weight. Of course, it is often practical to administer the daily dose of compound in portions, at various hours of the day.
However, in any given case, the amount of compound administered will depend on such factors as the potency of the specific estrogen agonist / antagonist, the solubility of the compound, the formulation used and the route of administration.
For (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol, L-tartrate salt, a preferred dosage range for humans is about 0.025 mglday/kg body weight to about 1 mg/day/kg body weight. A more preferred dosage range is about 0.25 mg/day/kg body weight to about 0.5 mg/day/kg body weight.
Methods of formulation are well known in the art and are disclosed, for example, in Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa., 19th Edition (1995). Pharmaceutical compositions for use within the present invention can be in the form of sterile, non-pyrogenic liquid solutions or suspensions, coated capsules, suppositories, lyophilized powders, transdermal patches or other forms known in the art.
Capsules are prepared by mixing the compound with a suitable diluent and filling the proper amount of the mixture in capsules. The usual diluents include inert powdered substances such as starch of many different kinds, powdered cellulose, especially crystalline and microcrystalline celiulose,.sugars such as fructose, mannitol and sucrose, grain flours and similar edible powders.
Tablets are prepared by direct compression, by wet granulation, or by dry granulation. Their formulations usually incorporate diluents, binders, lubricants and disintegrators as well as the compound. Typical diluents include, for example, various types of starch, lactose, mannitol, kaolin, calcium phosphate or sulfate, inorganic salts such as sodium chloride and powdered sugar. Powdered cellulose derivatives are also useful. Typical tablet binders are substances such as starch, gelatin and sugars such as lactose, fructose, glucose and the like. Natural and synthetic gums are also convenient, including acacia, alginates, methylcellulose, polyvinylpyrrolidine and the like. Polyethylene glycol, ethylcellulose and waxes can also serve as binders.
A lubricant may be necessary in a tablet formulation to prevent the tablet and punches from sticking in the die. The lubricant is chosen from such slippery solids as talc, magnesium and calcium stearate, stearic acid and hydrogenated vegetable oils.
Tablet disintegrators are substances that facilitate the disintegration of a tablet to release a compound when the tablet becomes wet. They include starches, ~ clays, celluloses, algins and gums, more particularly, com and potato starches, methylcellulose, agar, bentonite, wood cellulose, powdered natural sponge, cation-exchange resins, alginic acid, guar gum, citrus pulp and carboxymethylcellulose, for example, may be used as well as sodium lauryl sulfate.
Tablets are often coated with sugar as a flavorant and sealant, or with film-forming protecting agents to modify the dissolution properties of the tablet.
The compounds may also be formulated as chewable tablets, by using large amounts of pleasant-tasting substances such as mannitol in the formulation, as is now well-established in the art.
When it is desired to administer a compound as a suppository, the typical bases may be used. Cocoa butter is a traditional suppository base, which may be modified by addition of waxes to raise its melting point slightly. Water-miscible suppository bases comprising, particularly, polyethylene glycols of various molecular weights are in wide use.
The effect of the compounds may be delayed or prolonged by proper formulation. For example, a slowly soluble pellet of the compound may be prepared and incorporated in a tablet or capsule. The technique may be improved by making pellets of several different dissolution rates and filling capsules with a mixture of the pellets. Tablets or capsules may be coated with a film which resists dissolution for a predictable period of time. Topical formulations may be designed to yield delayed and/or prolonged percutaneous absorption of a compound. Even the parenteral preparations may be made long-acting, by dissolving or suspending the compound in oily or emulsified vehicles which allow it to disperse only slowly in the serum.
The term "prodrug" means a compound that is transformed in vivo to yield a cor~npound of the present invention. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A good discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, °Pro-drugs as Novel Delivery Systems," Vol. 14 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
For example, if a compound of the present invention contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as (C,-C$)alkyl, (C2-C~2)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C~-C2)alkylamino(Cz-C3)alkyl (such as (3-dimethylaminoethyl), carbamoyl-(C,-C2)alkyl, N,N-di(C~-CZ)alkylcarbamoyl-(C~-C2)alkyl and piperidino-, pyrrolidino- or morpholino(C2-C3)alkyl.
Similarly, if a compound of the present invention comprises an alcohol functional group, a prodrug can be formed by the replacement of the hydrogen atom of the alcohol group with a group such as (C,-Cg)alkanoyloxymethyl, 1-((C~-C6)alkanoyloxy)ethyl, 1-methyl-1-((C,-Cg)alkanoyloxy)ethyl, (C~-Cs)alkoxycarbonyloxymethyl, N-(C~-Cs)alkoxycarbonylaminomethyl, succinoyl, (C,-C6)alkanoyl, a-amino(C,-C4)alkanoyl, arylacyl and a-aminoacyl, or a-aminoacyl-a-aminoacyl, where each a-aminoacyl group is independently selected from the naturally occurring L-amino acids, P(O)(OH)2, -P(O)(O(C~-Cs)alkyl)2 or glycosyl (the radical resulting from the removal of a hydroxyl group of the hemiacetal form of a carbohydrate).
If a compound of the present invention comprises an amine functional group, a prodrug can be formed by the replacement of a hydrogen atom in the amine group with a group such as R"-carbonyl, R"O-carbonyl, NRXRX'-carbonyl where Rx and RX' are each independently (C~-C~°)alkyl, (C3-C~)cycloalkyl, benzyl, or R"-carbonyl is a natural a-aminoacyl or natural a-aminoacyl-natural a-aminoacyl, -C(OH)C(O)OY" wherein Y" is H, (C,-Ce)alkyl or benzyl, -C(OY"°) Y"' wherein YXo is (C,-C4) alkyl and YX' is (C,-Ce)alkyl, carboxy(C~-C6)alkyl, amino(C~-C4)alkyl or mono-N- or di-N,N-(C~-Cs)alkylaminoalkyl, -C(Y"2) Y"3 wherein Y"2 is H or methyl and Y"3 is mono-N- or di-N,N-(C,-C6)alkylamino, morpholino, piperidin-1-yl or pyrrolidin-1-yi.
Advantageously, the present invention also provides kits for use by a cansumer to improve or maintain urogenital health. The kits comprise a) a pharmaceutical composition comprising an estrogen agonist / antagonist and a pharmaceutically acceptable carrier, vehicle or diluent; and b) instructions describing a method of using the pharmaceutical compositions to improve or maintain urogenital health. The instructions may also indicate that the kit is to improve or maintain urogenital health while substantially reducing the concomitant liability of adverse effects associated with estrogen administration.
A "kit" as used in the instant application includes a container for containing the pharmaceutical compositions and may also include divided containers such as a divided bottle or a divided foil packet. The container can be in any conventional shape or form as known in the art which is made of a pharmaceutically acceptable material, for example a paper or cardboard box, a glass or plastic bottle or jar, a re-sealable bag (for example, to hold a "refill" of tablets for placement into a different container), or a blister pack with individual doses for pressing out of the pack according to a therapeutic schedule. The container employed can depend on the exact dosage form involved, for example a conventional cardboard box would not generally be used to hold a liquid suspension. It is feasible that more than one container can be used together in a single package to market a single dosage form.
For example, tablets may be contained in a bottle that is in turn contained within a box.
An example of such a kit is a so-called blister pack. Blister packs are well known in the packaging industry and are being widely used for the packaging of pharmaceutical unit dosage forms (tablets, capsules, and the like). Blister packs generally consist of a sheet of relatively stiff material covered with a foil of a preferably transparent plastic material. During the packaging process, recesses are formed in the plastic foil. The recesses have the size and shape of individual tablets or capsules to be packed or may have the size and shape to accommodate multiple tablets and/or capsules to be packed. Next, the tablets or capsules are placed in the recesses accordingly and the sheet of relatively stiff material is sealed against the plastic foil at the face of the foil which is opposite from the direction in which the recesses were formed. As a result, the tablets or capsules are individually sealed or collectively sealed, as desired, in the recesses between the plastic foil and the sheet. Preferably the strength of the sheet is such that the tablets or capsules can be removed from the blister pack by manually applying pressure on the recesses whereby an opening is formed in the sheet at the place of the recess. The tablet or capsule can then be removed via said opening.
It may be desirable to provide a written memory aid, where the written memory aid is of the type containing information and/or instructions for the physician, pharmacist or patient, e.g., in the form of numbers next to the tablets or capsules whereby the numbers correspond with the days of the regimen which the tablets or capsules so specified should be ingested or a card which contains the same type of information. Another example of such a memory aid is a calendar printed on the card e.g., as follows "First Week, Monday, Tuesday," . . . etc . . . .
"Second Week, Monday, Tuesday, . . ." etc. Other variations of memory aids will be readily apparent. A "daily dose" can be a single tablet or capsule or several tablets or capsules to be taken on a given day.
Another specifrc embodiment of a kit is a dispenser designed to dispense the daily doses one at a time. Preferably, the dispenser is equipped with a memory-aid, so as to further facilitate compliance with the regimen. An example of such a memory-aid is a mechanical counter which indicates the number of daily doses that has been dispensed. Another example of such a memory-aid is a battery-powered micro-chip memory coupled with a liquid crystal readout, or audible reminder signal which, for example, reads out the date that the last daily dose has been taken and/or reminds one when the next dose is to be taken.
It is noted that an estrogen agonist / antagonist can be used in combination with other different estrogen agonists / antagonists to maintain or improve urogenital health. In addition, estrogen agonists /antagonists can be used in combination with estrogen. Estrogen agonists / antagonists can also be used in combination with one or more additional compounds that are therapeutically useful to improve or maintain urogenital health. For example, estrogen agonists / antagonists can be used in combination with compounds that are used to treat urinary incontinence, anal incontinence, vaginal infections, urinary infections, vaginal dryness, vaginal itching, or pelvic floor integrity, including vaginal prolapse. Examples of additional compounds that can be used in combination with an estrogen agonist / antagonist include Detrol~
and anti-fungal and anti-bacterial products.
In addition, an estrogen agonist / antagonist can be used in combination with agents that can be used to acidify (i.e., lower pH) the urinary tract and/or vagina.
Examples of such agents include potassium acid phoshate and sodium acid phosphate.
An estrogen agonist / antagonist can be used in combination with a cGMP
elevator agent to treat the conditions disclosed herein.
Prefer-ed as the cGMP elevator are cGMP phosphdiesterase (PDE) inhibitors. cGMP PDE inhibitors that are selective for cGMP PDEs rather than cyclic adenosine 3',5'-monophosphate phosphodiesterases (CAMP PDEs) and that are selective inhibitors of the cGMP PDE" isoenzyme are particularly preferred.
Such particularly preferred cGMP PDE inhibitors are disclosed in US patents 5,250,534;
5,346,901; 5,272,147; and in the international patent application WO 94/28902.
Preferred cGMP PDE~ inhibitors include compounds of formula (VII):
R3c0 HN
(vll) Rac wherein:
R'c is H; C~-C3 alkyl; C~-C3 perfluoroalkyl; or C3-C5 cycloalkyl;
Rzc is H; C,-Cs alkyl optionally substituted with C3-Cs cycloalkyl; C,-C3 perfluoroalkyl; or C3-Cs cycloalkyl;
R3c is C,-Cs alkyl optionally substituted with C3-Cs cycloalkyl; C,-Cs perfluoroalkyl; C3-CS cycloalkyl; C3-Cs alkenyl; or C3-Cs alkynyl;
R4c is C~-C4 alkyl optionally substituted with OH, NRSCRsc, CN, CONR5cRsc or C02R'c; C~-C4 alkenyl optionally substituted with CN, CONRSCRsc or COZR'c; C~-alkanoyl optionally substituted with NRSCRsc; (hydroxy)C2-C4 alkyl optionally substituted with NRSCRsc; (C2-C3 alkoxy)C~-C2 alkyl optionally substituted with OH or NRSCRsc; CONRSCRsc; C02R'c; halo; NRSCRsc; NHS02NR5cRsc; NHS02R8c;
SOZNR9cR'°c or phenyl, pyridyl, pyrimidinyl, imidazolyl, oxazolyl, thiazolyl, thienyl or triazolyl any of which is optionally substituted with methyl;
R5c and Rsc are each independently H or C,-C4 alkyl, or together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino, 4-N(R"c)-piperazinyl or imidazolyl group wherein said group is optionally substituted with methyl or OH;
R'c is H or C,-C4 alkyl;
Rsc is C,-C3 alkyl optionally substituted with NRSCRsc;
R9c and R'°c together with the nitrogen atom to which they are attached form a pyrrolidinyl, piperidino, morpholino or 4-N(R'ZC)-piperazinyl group wherein said group is optionally substituted with C~-C4 alkyl, C,-C3 alkoxy, NR'3cR'4c or CONR'3cR'4c;
R"C is H; C,-C3 alkyl optionally substituted with phenyl; (hydroxy)C~-C3 alkyl; or C,-C4 alkanoyl;
R'x is H; C,-Cs alkyl; (C1-C3 alkoxy)C~-Cs alkyl; (hydroxy)CrCs alkyl;
(RtscR,acN)C2-Ce alkyl; (R'~R'4cNOC)C,-Cs alkyl; CONR'3cR'"c; CSNR'3cR'4c; or C(NH)NR'3cR'''c; and R'3~ and R'4~ are each independently H; C~-C4 alkyl; (C~-C3 alkoxy)C2-C4 alkyl;
or (hydroxy)C2-C4 alkyl; and pharmaceutically acceptable salts thereof.
Prefers-ed cGMP PDEv inhibitors include 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1 H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxy-phenyl]sufonyl]-4-methylpiperazine (sildenafil) which has the structure of formula (VIII):
N
CH3CHz0 H
O ~ H3 (VIII) and pharmaceutically acceptable salts thereof; the compound having the structure of formula (IX):
i i . . .....
O ~ H3 N~
\N
J ~H2~
c~
(IX) and pharmaceutically acceptable salts thereof; and the compound 3-ethyl-5-{5-[(4-ethylpiperazino) sulphonyl]-2-(2-methoxyethoxy)pyrid-3-yl}-2-(2-pyridylmethyl)-6,7-dihydro-2H-pyrazolo[4,3-d]pyrimidin-7-one of formula (X):
O
ni / v O=S=
N
N
J
(X) The compound of formula (IX) is disclosed, for example, in US Patents 5,272,147 and 5,426,107.
A preferred pharmaceutically acceptable salt of sildenafil for use in this invention is the citrate salt, and a preferred dosage range is from about 1 mg to about 100 mg.
Also preferred as cGMP PDE~ inhibitors are compounds disclosed in WO
95/19978 having the formula (XI):
~N_R~°
N Ra°
N
~° O
(XI) and salts and solvates thereof, in which:
R°° represents hydrogen, halogen or C,-Csalkyl,;
R'° represents hydrogen, C~-Csalkyl, C2-Csalkenyl, Cz-Csalkynyl, haloC,-Csalkyl, C3-CBcycloalkyl, C3-C$cycloaIkyIC,-C3alkyl, arylC~-C3alkyl or heteroarylC~-C3alkyl;
R2° represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally A
substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atams and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R3° represents hydrogen or C,-C3alkyl, or R'° and R3° together represent a 3- or 4-membered alkyl or alkenyl ring.
A preferred group of compounds having formula Xla (also disclosed in WO
95!19978) includes compounds of the formula:
~N_R1D
N
N
~° O
(Xla) and salts and solvates thereof, in which:
R°° represents hydrogen, halogen or C~-Csalkyl;
R'° represents hydrogen, C,-CBalkyl, haloC,-Cealkyl, C3-Cscycloalkyl, C3-CBcycloalkyl-C~-C3alkyl, arylC~-C3alkyl or heteroarylC,-C3alkyl; and R2° represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally A
substituted bicyclic ring attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen.
cGMP elevators of the present invention include produgs, geometric isomers, stereoisomers, hydrates, tautomers and salts of the described compounds.
Suitable cGMP PDE inhibitors also include those disclosed in the following US patents:
a 5-substituted pyrazolo[4,3-d]pyrimidine-7-one disclosed in US 4,666,908;
a griseolic acid derivative disclosed in any of US 4,634,706, 4,783,532, 5,498,819, 5,532,369, 5,556,975, and 5,616,600;
a 2-phenylpurinone derivative disclosed in US 4,885,301;
a phenylpyridone derivative disclosed in US 5,254,571;
a fused pyrimidine derivative disclosed in US 5,047,404;
a condensed pyrimidine derivative disclosed in US 5,075,310;
a pyrimidopyrimidine derivative disclosed in US 5,162,316;
a purine compound disclosed in US 5,073,559;
a quinazoline derivative disclosed in US 5,147,875;
a phenylpyrimidone derivative disclosed in US 5,118,686;
an imidazoquinoxalinone derivative or its aza analog disclosed in US
5,055,465 and 5,166,344;
a phenylpyrimidone derivative disclosed in US 5,290,933;
a 4-aminoquinazoline derivative disclosed in US 5,436,233 or 5,439,895;
a 4,5-dihydro-4-oxo-pyrrolo[1,2-a]quinoxaline derivative disclosed in US
5,405,847;
a polycyclic guanine derivative disclosed in US 5,393,755;
a nitogenous heterocyclic compound disclosed in US 5,576,322;
a quinazoline derivative disclosed in US 4,060,615;
a 6-heterocyclyl pyrazolo[3,4-d]pyrimidin-4-one disclosed in US 5,294,612;
and a 4-aminoquinazoline derivative disclosed in US 5,436,233;
Other disclosures of cGMP PDE inhibitors include:
European patent application (EPA) publication no. 0428268;
European patent 0442204;
International patent application publication no. WO 94/19351;
Japanese patent application 5-222000;
European Journal of Pharmacology, 251, (1994), 1;
International patent application publication no. WO 94/22855;
a pyrazolopyrimidine derivative disclosed in European patent application 0636626;
a 4-aminopyrimidine derivative disclosed in European patent application 0640599;
an imidazoquinazoline derivative disclosed in International patent application W095/06648;
an anthranilic acid derivative disclosed in International patent application W095/18097;
a tetracyclic derivative disclosed in International patent application W095/19978;
an imidazoquinazoline derivative as disclosed in European patent application 0668280; and a quinazoline compound disclosed in European patent application 0669324.
The cGMP PDE inhibition of a compound can be determined by standard assays known to the art, for example as disclosed in US 5,250,534. Compounds that are selective inhibitors of cGMP PDE relative to cAMP PDE are preferred, and determination of such compounds is also taught in US 5,250,534. Particularly preferred are compounds that selectively inhibit the PDEv isoenzyme, as disclosed in WO 94/28902.
In addition, an estrogen agonist / antagonist can be used in combination with antibiotics such as azithromycin and/or antifungals such as fluconazole and vorconazole. Such combinations are particularly useful for treating vaginal or urinary bacterial or yeast infections.
The additional compounds that can be administered with an estrogen agonist / antagonist can be administered in the same dosage form or in different dosage forms. Likewise, the additional compounds can be administered at the same time as the estrogen agonist /antagonist or at different times. All combinations of dosage form and times are contemplated.
It is also noted that an estrogen agonist / antagonist can be administered using a topical dosage form such as a patch that is placed on the skin or an ointment that is rubbed on the skin. Such a dosage form can be used to administer other compounds that can be used in combination with an estrogen agonist /
antagonist. In one embodiment, the estrogen agonist / antagonist is administered in combination with one or more additional compounds. In another embodiment, the additional compounds are administered using a topical dosage form and the estrogen agonist antagonist is administered using a different dosage form such as a tablet.
The methods of measuring vaginal health involve an evaluation of vaginal health symptoms and a physical examination to determine physiological markers of vaginal health. The methods may also include a measurement of vaginal and/or urinary tract infection frequency and/or frequency of urinary incontinence.
The evaluation of pathological vaginal symptoms and subject-perceived vaginal health status is self-evaluated by the subject.
Measurements that are made during a gynecological examination include a vaginal pH measurement and a determination of vaginal maturation index.
Vaginal pH measurements are performed first during an examination and always prior to vaginal maturation index measurement or a PAP smear. If, at the beginning of the examination, a significant amount of lubricant is required to insert the speculum, the pH may be measured prior to the insertion of the speculum.
Vaginal pH measurements may be made with a single use, disposable pH
probe such as the pHem-AIertT"" pH probe (Imagyn Medical Technologies, Inc., Costa Mesa, CA). The pH probe is removed from packaging, inserted into the outer 1/3 of the vagina, and held against the lateral sidewall for about 2 seconds to moisten the paper. Contact between the pH probe and blood or cervical mucous should be avoided as the pH of these substances is generally neutral. The pH
probe is then removed and immediately compared to the pH color chart accompanying the pH probe to determine the pH of the vagina.
The vaginal maturation index represents the degree of proliferation and maturation of vaginal cells. The results are reported as percentages of parabasal, intermediate, and superficial cells as determined by techniques known in the art.
The vaginal maturation index smear must be taken prior to the PAP smear. A
commercially available kit for cytological specimen collection may be used (PAP
PakT"", Medical Packaging Corp., Camarillo, CA) to obtain the maturation index specimen. Generally, a rounded spatula end is used to take a gentle scraping from the mid-third lateral area of the vagina and applied to a microscope slide.
The sample must not be taken from the cervix or any other area of the vagina. The sample must also be collected from a healthy area free from inflammation, infection, ulceration, debris, or other contaminants. The preparation is immediately fixed by flooding the entire slide with standard cytology fixative. The fixative may be a standard fixative for cytology specimens such as that included in the PAP
PakT""
specimen collection kit. Once the fixative has dried, the specimen is evaluated microscopically and the maturation index determined.
The subject self-assessment of vaginal health is performed with a subjective vaginal health questionnaire. Typically, the questionnaire is performed in private and the results kept confidential. The questionnaire may include an envelope that is specially encoded to later identify the treatment that the subject is undergoing.
Examples of the questions and the ratings for questions are shown in Table 1.
An additional question may be added in subsequent questionnaires following administration of the baseline questionnaire, which question would ask: "Have you had any positive or negative vaginal changes since you have been taking the study medication?" This question may be coupled to a multiple-point ratings scale ranging from "mostly positive changes," to "moderately positive changes," to "mildly positive changes," to "no changes," to "mildly negative changes," to "moderately negative changes," to "mostly negative changes."
Table 1 : Subjective Vaginal Health Questionnaire Questions Question Select Response or Report Number How many children haveNatural Delivery?
you had 1 by: Cesarean Section?
How many vaginal infections have you had in the last 6 months?
How many urinary tract infections have you had in the last 6 months?
a) No Leakage (never use protection)?
b) Mild Leakage (no protection necessary)?
c) Moderate Leakage (occasionally wear What is the severity of any urinary protection)?
incontinence that you d) Moderately Severe Leakage (regularly wear experience?
protection)?
e) Severe Leakage (must change protection more than 2 times per day)?
a) When laughing, coughing, straining or If you experience any physically active?
amount of urinary incontinence, b) Leakage is uncontrollable and when does is preceded by it occur? a strong urge or need to urinate.
c) Leakage occurs without apparent cause.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal closely represents dryness and 7 representing extreme your degree of vaginal vaginal dryness? dryness.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal closely represents itching or irritation and 7 representing your degree of extreme vaginal itching or vaginal itching or irritation.
irritation?
Are you taking any products to g assist with vaginal dryness, irritation or itching?
What is your overall No Problems.
vaginal health. Mild Problems.
Question Select Response or Report Number Moderate Problems.
Moderately Severe Problems.
Severe Problems.
a) None What is the occurrence b) Rare (less than 1 per month) and frequency of any type c) Infrequent (1-3 times per of sexual month) activity? d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) a) None What is the occurrence b) Rare (less than 1 per month) of orgasm 11 (bY any means) with c) Infrequent (1-3 times per sexual month) activity? d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) Has anything happened in your (e~g~> change in health status or change in 12 personal life to decreaserelationships, etc.) your interest in sexual activity?
When the present assessment of vaginal nealtn metnoas are usea to evaluate drug efficacy or efficacy of other therapeutic methods, a vaginal health evaluation is made at the beginning of treatment. An additional evaluation is made one or more times during the course of or at the end of treatment such as every six 5 manths during the course of the study.
An important aspect of the present invention is the standardized assessment of pelvic organ prolapse and pelvic floor dysfunction. The present method can use a standardized system of terminology and grading from Baden, W.
and Walter, T., Surgical Repair of Vaginal Defects, Philadelphia, JB
Linnincott, 10 1992 and Bump, R.C. et al., The standardization of terminology of female pelvic organ prolapse and pelvic floor dysfunction, Am. J. Obstet. Gynecol. 175:10-17, 1996.
Exam variables are controlled so that accurate measurements may be made over the period of observation that may range anywhere from 6 months to 2 years or more. It is important, therefore, that certain examination variables be held constant for the duration such as: (i) position of the subject during examination; (ii) type of exam table or chair; (iii) type of specula or retractors; (iv) type of straining (Valsalva maneuver or cough); (v) fullness of bladder (void prior to exam);
and (vi) content of rectum (is stool present on rectal exam?).
Vaginal prolapse is graded on a 0 to 4 scale for the following types of prolapse: anterior wall urethrocele; anterior wall cystocele; superior wall uterine prolapse, posterior wall enterocele; and posterior wall rectocele. All prolapses are assigned a grade as determined in Table 2.
Table 2: Conditions Corresponding to Prolapse Grade Grade Criteria for Assigning Grade Normal position inside the mid-vaginal axis for anterior posterior wall Grade 0 prolapse and above the ischial spines for cervical or vaginal cuff. By definition, the most apical point is -3 cm superior to the hymen.
If the prolapse crosses the respective thresholds, and descends halfway Grade 1 to the hymen.
Grade 2 Descent to the hymen.
Grade 3 Descent 2 cm beyond the hymen.
Maximum possible descent for each site. A complete eversion is -5 cm Grade 4 .
beyond the hymen.
For quantitation of pelvic organ position and prolapse, the totlowing conditions apply: (i) the prolapse must be evaluated relative to a fixed point of reference; (ii) the ischial spines are reference for cervix or vaginal cuff prolapse; (iii) the vaginal midline axis will serve as a landmark for anterior and posterior wall prolapse; and (iv) the hymen will be the landmark for any prolapse extending beyond the ischial spines or the vaginal midline axis. The procedure for visualization of the prolapse is as follows:
(1 ) If an enterocele is suspected or the grade is uncertain, the examination is performed while the subject is standing.
(2) A posterior speculum blade or fingers are inserted to the vaginal apex, perineum is depressed, strain elicited, and withdrawal accomplished slowly to observe for prolapse and grade.
(3) The procedure is repeated by moving the speculum anteriorly to grade enterocele and rectocele if enterocele and rectocele are inadequately visualized in (2) above.
Finally, external urogenital measurements are made in centimeters. As the propensity of pelvic prolapse increases as the ratio of genital hiatus to perineal body measurement increases, the genital hiatus and perineal body are measured as follows:
Genital hiatus: Distance from the middle of the external meatus to the posterior mid-line hymen.
Perineal body: Distance from the posterior margin of the genital hiatus to the mid-anal opening.
During the examination for pelvic organ prolapse and pelvic floor dysfunction, objective measurements may also be made to evaluate the subject's vaginal health. These measurements may include measurements of blood estrogen and testosterone levels, measurement of vaginal pH, and measurement of the vaginal maturation index.
An internal vaginal health evaluation may be performed with continuously variable scale used under the following guidelines: The examiner is presented with a printed line of between 3 and 20 centimeters in length, preferably between 6 and 15 centimeters in length and most preferably 10 centimeters in length. The line is scaled with axis markers corresponding to degrees of internal vaginal health.
For example, on a horizontal line, 10 centimeters in length, one end of the line may be marked with the numeral (I), the midpoint of the line marked with the numeral (II) and the end of the line opposite of numeral (I) is marked with the numeral (III). The numerals I-III are indicated to correspond to the following condition:
(I) No rugae, elasticity non-existent, friable and bleeds to the touch, mucosa very pale, very dry, stenotic, narrow vaginal apex.
(II) Few rugae, mild elasticity, mucosa pale in color (not pink), loss of some moisture, slightly stenotic, mild narrowing of vaginal apex.
(III) Rugae present, good elasticity, pink, roboust mucosa, good vaginal moisture, normal vaginal apex with good depth.
The examiner is instructed to place a mark on the line representing the continuum of vaginal conditions from numerals I-III that best describes the internal evaluation.
In addition to the internal evaluation, an external evaluation may be obtained describing, for example, the appearance of pubic hair (i.e. very scant, scant, moderate, normal, excessive) and the condition of the labia (i.e. full thickness, mild vulWar regression, moderate vulvar regression (atrophic labia) or labial fusion (severe atrophy)).
i i The data obtained from the vaginal examination and tests described above are used in their totality to assess the vaginal health of a patient. The methods can be used to determine if a compound that has been administered to a patient has affected vaginal health, or the methods can be used to help a clinician assess vaginal health for the purpose of making a diagnosis. The present methods can also be used to assess changes in vaginal heath over time.
Interestingly, through the use of a self-assessment questionnaire, it has been found that postmenopausal women taking the estrogen agonist/antagonist (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahyd ro-naphthalene-2-0l, D-tartrate salt reported an increased frequency of sexual intercourse and/or an increased number of orgasms and/or increased intensity of orgasms.
The examples set forth below are intended to illustrate specific embodiments of the present invention and are not intended to limit the scope of the specification, including the claims, in any manner. , EXAMPLES
Example 1: Improvement or Maintenance of UroQenital Health.
Effects of estrogen agonists / antagonists for improving or maintaining urogenital health are assessed in a patient population of postmenopausal women not undergoing hormone replacement therapy. The efficacy of the estrogen agonist/antagonist for improving or maintaining urogenital health is measured in a random, double-blind, placebo controlled clinical study.
Patients are randomly separated into either a treatment group or a placebo group. Patients are initially given a subjective vaginal health questionnaire before receiving placebo or estrogen agonist / antagonist. Treatment or placebo is initiated and continued for 6 months. The questionnaire is administered to all patients at 3 and 6 months.
The patient self-assessment of vaginal health is performed with a subjective vaginal health questionnaire. The questionnaire is performed in private and the results kept confidential. The questionnaire is specially encoded to later identify the treatment that the patient is undergoing. Examples of the questions are given in Table 1. An additional question is added in subsequent questionnaires following the baseline questionnaire which would ask: "Have you had any positive or negative vaginal changes since you have been taking the study medication?" This question is coupled to a multiple-point ratings scale ranging from "mostly positive changes,"
to "moderately positive changes," to Nmildly positive changes," to "no changes," to "mildly negative changes," to "moderately negative changes," to "mostly negative changes.°
Table 1 : Subjective Vaginal Health Questionnaire Questions Question Select Response How many children haveNatural Delivery?
you had by: Cesarean Section?
How many vaginal infections have you had in the last 6 months?
How many urinary tract infections 3 have you had in the last 6 months?
a) No Leakage (never use protection)?
b) Mild Leakage (no protection necessary)?
c) Moderate Leakage (occasionally wear What is the severity of any urinary protection)?
4 incontinence that you d) Moderately Severe Leakage (regularly wear experience?
protection)?
e) Severe Leakage (must change protection more than 2 times per day)?
a) When laughing, coughing, straining or If you experience any physically active?
amount of 5 urinary incontinence, b) Leakage is uncontrollable and when does is preceded by it occur? a strong urge or need to urinate.
c) Leakage occurs without apparent cause.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal 6 closely represents dryness and 7 representing extreme your degree of vaginal vaginal dryness? dryness.
What is the number Scale of 1 to 7 with 1 representing that most no vaginal 7 closely represents itching or irritation and 7 representing your degree of extreme vaginal itching or vaginal itching or irritation.
irritation?.
Are you taking any products to 8 assist with vaginal dryness, irritation or itching?
Question Select Response No Problems.
Mild Problems.
What is your overall vaginal g Moderate Problems.
health.
Moderately Severe Problems.
Severe Problems.
a) None What is the occurrenceb) Rare (less than 1 per month) and frequency of any type c) Infrequent (1-3 times per month) of sexual activity? d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) a) None What is the occurrenceb) Rare (less than 1 per month) of orgasm 11 (by any means) with c) Infrequent (1-3 times per month) sexual activity? ' d) Regular (1-3 times per week) e) Frequent (more than 3 times per week) Has anything happened in your (e~g~~ change in health status or change in 12 personal life to decrease your relationships, etc.) interest in sexual activity?
Claims (7)
1. A method for assessing vaginal health in a patient, the method comprising:
a) conducting a gynecological examination;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index;
d) determining vaginal prolapse;
e) administering a questionnaire to the patient;
and f) measuring plasma hormone levels, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
a) conducting a gynecological examination;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index;
d) determining vaginal prolapse;
e) administering a questionnaire to the patient;
and f) measuring plasma hormone levels, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
2. The method of claim 1, wherein the gynecological examination comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length.
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length.
3. The method of claim 2, wherein the gynecological exam further comprises an assessment of the quantity of pubic hair and the thickness of the vulva.
4. The method of claim 1, 2 or 3, wherein the plasma hormone levels that are measured include estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione.
5. The method of claim 1, 2, 3 or 4, wherein vaginal prolapse is determined by grading the prolapse using the following scale:
6. The method of claim 1, 2, 3 or 4, wherein the questionnaire comprises questions relating to:
1) the number of vaginal infections;
2) the number of urinary infections;
3) the amount of urinary leakage;
4) the degree of vaginal dryness;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient.
1) the number of vaginal infections;
2) the number of urinary infections;
3) the amount of urinary leakage;
4) the degree of vaginal dryness;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient.
7. ~A method for assessing vaginal health in a patient, the method comprising:
a) conducting a gynecological examination that comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length; and assessing the quantity of pubic hair and the thickness of the vulva;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index;
d) determining vaginal prolapse using the following scale:
e) administering a questionnaire to the patient, the questionnaire comprising questions relating to:
1) the number of vaginal infections in a specified time period;
2) the number of urinary infections in a specified time period;
3) the amount of urinary leakage in a specified time period;
4) the degree of vaginal dryness in a specified time period;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient; and f) measuring plasma levels of estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
a) conducting a gynecological examination that comprises an internal evaluation of the vagina in which the condition of the vagina is characterized by indicating the condition of the vagina on a continuum using I and III below as endpoints and II as the midpoint of the continuum:
I. no rugae, elasticity non-existent, mucosa is very pale, friable and bleeds to touch, no vaginal depth and very dry;
II. few rugae, loss of some moisture, mild elastic discomfort on exam, pale color, shortening of vaginal length; or III. normal estrogenized vagina, rugae, good elasticity, pink robust mucosa, good vaginal moisture and good vaginal length; and assessing the quantity of pubic hair and the thickness of the vulva;
b) measuring the pH of the vagina;
c) determining the vaginal cell maturation index;
d) determining vaginal prolapse using the following scale:
e) administering a questionnaire to the patient, the questionnaire comprising questions relating to:
1) the number of vaginal infections in a specified time period;
2) the number of urinary infections in a specified time period;
3) the amount of urinary leakage in a specified time period;
4) the degree of vaginal dryness in a specified time period;
5) the degree of vaginal itching; and 6) a subjective assessment of overall vaginal health by the patient; and f) measuring plasma levels of estradiol, luteinizing hormone, follicle-stimulating hormone, testosterone and androstenedione, whereby the data from steps a-f are considered in their totality in making an assessment of the vaginal health of the patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24078900P | 2000-10-16 | 2000-10-16 | |
US60/240,789 | 2000-10-16 | ||
CA002358938A CA2358938C (en) | 2000-10-16 | 2001-10-12 | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002358938A Division CA2358938C (en) | 2000-10-16 | 2001-10-12 | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2541348A1 true CA2541348A1 (en) | 2002-04-16 |
Family
ID=36646303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002541348A Abandoned CA2541348A1 (en) | 2000-10-16 | 2001-10-12 | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women |
Country Status (1)
Country | Link |
---|---|
CA (1) | CA2541348A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117510650A (en) * | 2023-11-08 | 2024-02-06 | 广西福莱明生物制药有限公司 | Protein for pelvic floor dysfunction and composition thereof |
-
2001
- 2001-10-12 CA CA002541348A patent/CA2541348A1/en not_active Abandoned
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117510650A (en) * | 2023-11-08 | 2024-02-06 | 广西福莱明生物制药有限公司 | Protein for pelvic floor dysfunction and composition thereof |
CN117510650B (en) * | 2023-11-08 | 2024-05-24 | 广西福莱明生物制药有限公司 | Protein for pelvic floor dysfunction and composition thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2358938C (en) | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women | |
KR100485856B1 (en) | Compositions And Methods Of Treatment For Conditions Responsive To Testosterone Elevation | |
JP5193196B2 (en) | Methods of treatment for atrophic vaginitis | |
KR20010098650A (en) | Compositions and methods for treating female sexual dysfunction | |
US20010056099A1 (en) | Method of reducing morbidity and the risk of mortality | |
US20150111861A1 (en) | Pharmaceutical Combination of Resveratrol and Progestin to Treat and/or Prevent Myoma and/or Endometriosis | |
JP2005504032A (en) | Pharmaceutical compositions, kits and methods comprising estrogen agonist / antagonist, estrogen and progestin combinations | |
CN102406650A (en) | Sex steroid precursors alone or in combination with selective estrogen receptor modulator for prevention and treatment of vaginal dryness and sexual dysfunction in postmenop | |
KR20220045198A (en) | GNRH antagonists for the treatment of estrogen-dependent disorders | |
AU779964B2 (en) | Therapy for andropause using estrogen agonists/antagonists and testosterone | |
CA2541348A1 (en) | Methods for assessing, improving, or maintaining urogenital health in postmenopausal women | |
WO2020089190A2 (en) | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |